CLINICAL STUDY PROTO COL
BPR -PIP-003
A multicent er, open- label ,single -arm, multiple -dose study to evaluate the safety, 
pharmacokinetics ,and efficacy of ceftobiprole medocaril in term and pre -term 
neonates and infants up to 3 months of age with late- onset sepsis
Protocol n umber / Version BPR -PIP-003 / 5.0
Compound Ceftobiprole medocaril
Phase of development Phase 3
IND number 64,407
EudraCT number 2022-001837-35
Date 9July 2024
Project Physician
Project Statistician
Sponsor Basilea Pharmaceutica International L td, Allschwil
Hegenheimermattweg 167b
4123 Allschwil, Switzerland
Confidentiality statem ent
All information contained in this document is confidential and proprietary information of Basilea 
Pharm aceutica International Ltd, Allschwil (‘Basilea’). This information is provided to you on a 
confidential basis as an Investigator or potential Investigat or, for review  by you, and for potential future 
discussion with an applicable Independent Ethics Committee / Institutional Review Board as needed. It 
may otherwise not be disclosed by you to any third party other than those members of your staff who have 
aneed to know, without prior written authorization from Basilea, except to the extent necessary to obtain 
informed consent from potential participants in the clinical study to which the document refers. If it is 
determined that disclosure to another third party is required by applicable law or regulations, the person 
to whom the information is disclosed must be informed that the information is confidential, and that it 
may not be further disclosed without prior w ritten authorization from Basilea.
Note: This is an electronically controlled document
[STUDY_ID_REMOVED]

 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 3of 69
PROTOCOL SYNOPSIS
TITLE: A multicenter , open -label, single -arm, multiple -dose study to 
evaluate the safety, pharmacokinetics, and efficacy of 
ceftobiprole medocaril in term and pre -term neonates and infants 
up to 3 months of age with late -onset sepsis
PROTOCOL NUMBER / 
VERSION :BPR -PIP-003 / 5.0
SPONSOR: Basilea Pharmaceutica International Ltd , Allschwil
STUDY PHASE: Phase 3
INDICATION: Treatment of late- onset sepsis in term and pre -term neonates and 
infants up to 3 months of age
IND NUMBER: 64,407
EUDRACT NUMBER: 2022-001837-35
DATE: 9July 2024
OBJECTIVES 
Primary objectives
To characteri se the safety profile of ceftobiprole medocaril in term and pre-term neonates and 
infants up to 3 months of age with late -onset sepsis (LOS).1
Secondary objectives
To assess in term and pre -term neonates and infants up to 3 months of age with LOS treated with 
ceftobiprole medocaril :
Pharmacokinetics (PK) of ceftobiprole
Clinical response
All-cause mortality
Microbiological response
STUDY OVERVIEW
Study design
This is a m ulticenter, open -label, single -arm, multiple -dose study of intravenous (IV) ceftobiprole
medocaril in term and pre -term neonates and infants up to 3 months of age with LOS. Ceftobiprole 
may be combined with ampicillin and/or an aminoglycoside based on the Investigator’s judgement , 
local standard of care ,and/or isolated or presumed pathogens.
                                                
1Ceftobiprole medocaril is the water -soluble prodrug of the active moiety ceftobiprole. Unless referring specifically to 
the prodrug, the term ‘ceftobiprole’ is used throughout the remainder of this protocol, and all doses are of ceftobiprole 
equivalents.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 5of 69
PATIENT POPULATION
At least eight patients, at least two term (gestational age ≥ 37 weeks) and at least sixpre-term 
(gestational age ≥24 to 36 weeks), with post -natal age ranging from ≥3 days to ≤3 months. 
INVESTIGATIONAL PRODUCT(S)
Ceftobiprole medocaril powder for concentrate for solution for infusion .
NUMBER OF SITES/LOCATIONS
Approximately tensites in Europe and USA, with additional sites and locations possible.
DOSE / ROUTE / REGIMEN
Ceftobiprole medocaril : 7.5mg/kg every 12 hours to 15mg/kg every 8 hours , (depending on age 
and weight) administered IV as a 2-hour infusion, with dose adjusted according to gestational and 
post-natal ages. Neonates and infants with a body weight < 4kg will receive a maximum of 
10mg/kg/dose. The duration of treatment with ceftobiprole is 3–10 days, but may be extended to 
14days if considered clinically necessary by the Investigator.
Ampicillin and/or an aminoglycoside (gentamicin, tobramycin, or amikacin), if applicable: dosage 
and administration according to manufacturer ’s instructions and/orlocal standard of care. The 
treatment duration of ampicillin and/or the aminoglycoside, if added, is at the discretion of the 
Investigator.
KEY INCLUSION CRITERIA
(The full list of inclusion criteria is provided in Section 4.2of the protocol .)
Informed consent from parent(s) or other legally -acceptable representative (LAR) to participate
in the study
Male or female, with a gestational age of ≥ 24 weeks and a post-natal age ranging from ≥ 3days
to ≤ 3months
Diagnosis of documented or presumed bacterial LOS requiring administration of systemic
antibiotic treatment
Sufficient vascular access to receive study dr ug and to allow blood sampling at a site separate
from the study drug infusion line
KEY EXCLUSION CRITERIA
(The full list of exclusion criteria is provided in Section 4.3of the protocol .)
Refractory septic shock not responding to 60minutes of vasopressor treatment within 48 hou rs
before enrollment
Proven ventilator -associated pneumonia
Proven central nervous system infection (e.g., meningitis, brain abscess)
Proven osteomyelitis, infective endocarditis, or necroti sing enterocolitis
Impaired renal function or known significant renal disease, as evidenced by an estimated
glomerular filtration rate (using the Schwartz formula or other applicable formula) calculated
to be less than 2/3 of normal for the applicable age group, OR urinary output <0.5mL/kg/h
(measured over at least 8 hours), OR requirement for dialysis
Progressively fatal underlying disease, or life expectancy < 30 days
Use of systemic antibacterial therap y for longer than 72 hours within 7days before start of
study medication
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 6of 69
Participation in another clinical study with an investigational product within 30days of 
enrollment in the current study
MAIN STUDY ENDPOINTS
Primary endpoint
Safety and tolerability (Safety population) :
Adverse events (AEs), serious AEs, deaths, and discontinuations due to AEs during 
treatment with ceftobiprole and at the end-of-treatment (EOT ), test-of-cure (TOC ), and last 
follow -up ( LFU )visits
Clinical laboratory t ests, vital signs, and physical examination findings
Secondary endpoints
Pharmacokinetics (PK population) :
Plasma levels of ceftobiprole , ceftobiprole medocaril ,and open- ring metabolite
Efficacy :
Clinical cure rate at the EOT and TOC visits (ITT and CE populations)
All-cause mortality through Day 28 (ITT population)
Microbiological eradication or presumed eradication rate at the EOT and TOC visits (mITT 
and ME populations)
Improved signs and symptoms of LOS at the Day 3, EOT, and TOC visits (ITT and CE 
populations)
STATISTICAL ANALYSIS
Key analysis populations
Intent -to-treat (ITT) population / Safety population
All patients enrolled in the study who received at least onedose of ceftobiprole .
Clinically E valuable (C E) population
Patients in the ITT population who received at least 48 hours of study drug
(i.e., four orsixinfusions of ceftobiprole as applicable) and had a completed overall clinical 
outcome assessment at the TOC visit, no major protocol deviations , and no concomita nt systemic 
non-study antibiotic therapy .
Microbiological Intent -to-treat (mITT) population
All patients in the ITT population with a valid pathogen identified at baseline.
Microbiologically Evaluable (ME) population
All patients in the CE analysis population with a valid pathogen identified at baseline and a 
microbiological outcome assessment at the TOC visit.
Pharmacokinetic s(PK) population
All patients who received at least one dose of ceftobiprole and had at least onesample of plasma 
concentration measurement obtained by the appropriate methodology.
Analyses
There will be no formal hypothesis testing. Descriptive statistics will be applied to the primary 
andsecondary endpoints as follows: number, mean, standard deviation, median, minimum, 
andmaximum will be provided for continuous variables, and frequency distributions (counts and 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 7of 69
percentages) will be shown for categorical variables. All variables will be summari sed overall 
andby gestational and post-natal agesas appropriate. Variables may be compared to baseline where 
applicable. Listings of individual patients’ data will also be produced.
ASSESSMENTS
Safety/tolerability
Safety will be assessed through summaries of AEs, clinical laboratory tests, vital signs, and physical 
examination findings. All safety analyses will be based on the safety population.
Pharmacokinetics
Plasma concentrations of ceftobiprole, ceftobiprole medocaril, and open -ring metabolite. 
Descriptive analyses of these concentrations will be summarised by timepoint for term and pre-term 
neonates with post -natal ag e up to 3 months.
Clinical effect
The following efficacy assessments will be analy sed using descriptive statistics:
Clinical and microbiological outcome a ssessments at the EOT and TOC visits (Section 5.6)
All-cause mortality through Day 28
Signs and symptoms of LOS at the Day 3, EOT, and TOC visits (Section 5.6)
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 8of 69
TABLE OF CONTENTS
PROTOCOL  SYNOPSIS .................................................................................................... 3
TABLE OF CONTENTS .................................................................................................... 8
LIST OF TABL ES............................................................................................................ 13
LIST OF FIGURES ........................................................................................................... 13
LIST OF APPENDICES ................................................................................................... 13
LIST OF ABBREVIATION S ........................................................................................... 14
1INTRODUCTION ...................................................................................................... 16
1.1 Disease ch aracteristics and study  drug ................................................................. 16
1.1.1 Disease characteristics .................................................................................... 16
1.1.2 Study  drug ...................................................................................................... 16
1.2 Nonclinical studies with ceftobiprole ................................................................... 17
1.2.1 Nonclinical pharmacod ynamics and activit y of ceftobiprole ......................... 17
1.2.2 Nonclinical pharmacokinetics ........................................................................ 17
1.2.3 Nonclinical toxicology ................................................................................... 18
1.3 Clinical studies with ceftobiprole......................................................................... 19
1.3.1 Completed Phase 3 clinical studies in adult patien ts...................................... 19
1.3.2 Completed studies in pediatric patients.......................................................... 20
1.3.2.1 Study  CSI-1006......................................................................................... 20
1.3.2.2 Study  BPR -PIP-001 .................................................................................. 21
1.3.2.3 Study  BPR -PIP-002 .................................................................................. 22
1.3.3 Benefit -risk assessment .................................................................................. 23
1.4 Study  rationale ..................................................................................................... 23
1.4.1 Summary  of stud y design ............................................................................... 24
1.4.2 Study  design rationale .................................................................................... 24
1.4.3 Dose rationale ................................................................................................. 24
2OBJECTI VES OF THE ST UDY ................................................................................ 25
2.1 Primary  objective ................................................................................................. 25
2.2 Secondary  objectives ............................................................................................ 26
3STUDY DESIGN ....................................................................................................... 26
3.1 Overview of study  design and dosing regimen .................................................... 26
3.2 Endpoints.............................................................................................................. 28
3.2.1 Primary  endpoint ............................................................................................ 28
3.2.2 Secondary endpoints ....................................................................................... 28
3.3 Treatment plan ..................................................................................................... 28
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 9of 69
3.3.1 Dose modifications......................................................................................... 28
3.3.2 Duration of treatment ..................................................................................... 28
3.3.3 Missed- dose management .............................................................................. 29
3.3.4 Overdose ......................................................................................................... 29
3.4 Data and Safet y Monitoring Board ...................................................................... 29
3.5 Definition of the end of the study ........................................................................ 29
4STUDY POPUL ATION ............................................................................................. 30
4.1 Target population ................................................................................................. 30
4.2 Inclusion criteria ................................................................................................... 30
4.3 Exclusion criteria ................................................................................................. 31
4.4 Patient withdrawal ................................................................................................ 32
4.5 Replacement of patients ....................................................................................... 33
4.6 Study  discontinuation ........................................................................................... 33
5SCHEDUL E OF ASSESSME NTS AND PROCEDURES........................................ 33
5.1 Summary  of schedule of assessments .................................................................. 33
5.2 Study  visits ........................................................................................................... 37
5.2.1 Screening visit / Baseline (Day  −2 to Day  1) ................................................. 37
5.2.2 Active treatment visits .................................................................................... 38
5.2.3 End-of- treatment visit ..................................................................................... 39
5.2.4 Test-of-cure visit ............................................................................................ 39
5.2.5 Last follow -up visit ......................................................................................... 40
5.3 Medical history  and concomitant medications ..................................................... 40
5.3.1 Medical history ............................................................................................... 40
5.3.2 Prohibited concomitant medications .............................................................. 40
5.3.3 Permitted concomitant medications ............................................................... 41
5.4 Microbiology  assessments ................................................................................... 41
5.5 Safety  assessments ............................................................................................... 41
5.5.1 Adverse event monitoring .............................................................................. 41
5.5.2 Physical examination ...................................................................................... 41
5.5.3 Vital signs and pulse oximetry ....................................................................... 42
5.5.4 Laboratory  parameters and PK sampling ....................................................... 42
5.5.5 Pregnancy  testing ............................................................................................ 43
5.6 Efficacy  assessments ............................................................................................ 43
5.6.1 Overall clinical outcome................................................................................. 43
5.6.2 All- cause mortalit y ......................................................................................... 44
5.6.3 Microbiological outcome ................................................................................ 44
5.6.4 Relapse at LFU ............................................................................................... 45
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 10of 69
5.6.5 Signs and s ymptoms of LOS .......................................................................... 45
5.7 Pharmacokinetic assessments ............................................................................... 45
6STUDY TREATMENT .............................................................................................. 46
6.1 Blinding................................................................................................................ 46
6.2 Randomization ..................................................................................................... 46
6.3 Packag ing and labelling ....................................................................................... 46
6.4 Shipping and storage conditions .......................................................................... 46
6.5 Preparation, presentation, and stability  of stud y drug .......................................... 46
6.6 Dosage and administration of study  drug ............................................................. 46
6.7 Compliance and drug- supply  accountability ........................................................ 47
6.7.1 Drug disposal .................................................................................................. 47
7SAFETY ..................................................................................................................... 48
7.1 Warnings and precautions.................................................................................... 48
7.1.1 Ceftobiprole.................................................................................................... 48
7.1.2 Ampi cillin / aminogly cosides ......................................................................... 48
7.1.3 Contraception and pregnancy ......................................................................... 48
7.2 Definitions............................................................................................................ 48
7.2.1 Adverse event ................................................................................................. 48
7.2.2 Serious adverse event ..................................................................................... 49
7.2.3 Adverse drug reaction ..................................................................................... 50
7.2.4 Suspected unexpected serious adverse reaction ............................................. 50
7.2.5 Adverse events of special interest .................................................................. 50
7.2.6 Further adverse event definitions ................................................................... 51
7.2.7 Special Situations ........................................................................................... 51
7.3 Evaluation of adverse events ................................................................................ 51
7.3.1 Grading of severit y......................................................................................... 51
7.3.2 Assessment of causality.................................................................................. 51
7.4 Handling of safety  information and collection periods ........................................ 53
7.4.1 Responsibilities and procedures ..................................................................... 53
7.4.2 Handling of safety  data during the pre- treatment period ................................ 53
7.4.3 Handling of safety  data during the treatment per iod and up to the last 
scheduled follow -up ....................................................................................... 53
7.4.3.1 Reporting procedures for adverse events that do not meet seriousness 
criteri a ....................................................................................................... 54
7.4.3.2 Reporting procedures for serious adverse events ..................................... 55
7.4.4 Follow -up of adverse events ........................................................................... 56
7.4.5 Handling of post -study  safet y data................................................................. 56
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 11of 69
7.4.6 Reporting and handling of pregnancies .......................................................... 56
7.5 Adverse events associated with an overdose or any  other Special Situation ....... 56
8STATI STICAL CONSIDER ATIONS AND ANALYTICA L PLAN ........................ 57
8.1 Study  endpoints .................................................................................................... 57
8.1.1 Primary  endpoint ............................................................................................ 57
8.1.2 Secondary endpoints ....................................................................................... 57
8.2 Analy sis populations ............................................................................................ 57
8.2.1 Intent -to-treat (ITT) population / Safety  population ...................................... 57
8.2.2 Clinically  Evaluable (CE) population ............................................................ 57
8.2.3 Microbiological Intent- to-treat (mITT) population ........................................ 57
8.2.4 Microbiologically  Evaluable (ME) population .............................................. 57
8.2.5 Pharmacokinetics (PK) population................................................................. 58
8.3 Sample size considerations .................................................................................. 58
8.4 Statistical and analy tical methods ........................................................................ 58
8.4.1 Primary  endpoint anal ysis.............................................................................. 58
8.4.1.1 Safety /tolerability  anal ysis........................................................................ 58
8.4.2 Secondary  endpoint analy ses.......................................................................... 58
8.4.2.1 Pharmacokinetic anal ysis.......................................................................... 58
8.4.2.2 Efficacy  anal yses...................................................................................... 59
8.4.3 Study  drug exposure and compliance ............................................................. 59
8.4.4 Prior and concomitant treatments................................................................... 59
8.4.5 Handling of missing data and discontinuations.............................................. 59
9STUDY ADMINI STRATION AND REGULATORY ASPE CTS............................ 59
9.1 Study  records ........................................................................................................ 59
9.1.1 Investigator Site File ....................................................................................... 59
9.1.2 Case report forms ........................................................................................... 59
9.1.3 Patient source documents ............................................................................... 60
9.1.4 Document retention and archiving ................................................................. 60
9.2 Clinical monitoring .............................................................................................. 60
9.3 Audits and inspections ......................................................................................... 61
9.4 Protocol amendments ........................................................................................... 61
9.5 Premature termination of the study ...................................................................... 61
9.6 Publication policy ................................................................................................. 61
10ETHI CS AND GOOD CLIN ICAL PRACTI CE........................................................ 62
10.1 Good clinical practice .......................................................................................... 62
10.2 Informed consent .................................................................................................. 62
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 12of 69
10.3 Patient confidentiality  and data protection ........................................................... 63
10.4 Independent Ethics Committees / I nstitutional Review Boards........................... 63
11PROTOCOL  VERSION HI STORY........................................................................... 64
12REFERENCES ........................................................................................................... 65
13APPENDI CES ............................................................................................................ 67
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 13of 69
LIST OF TABLES
Table 1 Key completed Phase 3 clinical studies in adult patients ...................19
Table 2 Completed clinical stu dies in pediatric patients .................................20
Table 3 Schedule of assessments .....................................................................34
Table 4 Local laboratory  parameters ...............................................................43
Table 5 Ceftobiprole dosing regimen for the treatment of neonates and 
infants with LOS .................................................................................47
LIST OF FIGURES
Figure 1 Overview of study  design ...................................................................27
LIST OF APPENDICES
Appendix 1 Renal function .....................................................................................67
Appendix 2 Investigator’s protocol signature page................................................69
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 14of 69
LIST OF ABBREVIATIONS
% fT >MIC Percentage of the dosing interval that free- drug 
concentrations are above the minimum inhibitory 
concentration
ABSSSI Acute bacterial skin and skin structure infection
ADR Adverse drug reaction
AE Adverse event
AESI Adverse event of special interest
ALT Alanine aminotransferase
AST Aspartate aminotransferase
CABP Community -acquired bacterial pneumonia
CE Clinically  Evaluable
CI Confidence Interval
Cmax Maximum concentration
CoNS Coagulase -negative staphy lococci
CRO Contract Research Organization
DSMB Data and Safet y Monitoring Board 
EC Ethics Committee
eCRF Electronic case report form
eGFR Estimated glomerular filtration rate
EOT End-of- treatment
GCP Good Clinical Practice
GFR Glomerular filtration rate
HABP Hospital -acquired bacterial pneumonia
IB Investigator’s Brochure
ISF Investigator Site File
ITT Intent -to-treat
IV Intravenous
LAR Legally -acceptable representative
LFU Last follow -up
LOS Late-onset sepsis
ME Microbiologically  Evaluable
MIC Minimum inhibitory  concentration
mITT Microbiological Intent- to-treat
MRSA Methicillin -resistant Staphylococcus aureus
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 15of 69
NOAEL No-observed-adverse-effect level
PD Pharmacod ynamic(s)
PK Pharmacokinetic(s)
q12h Every  12 hours
q8h Every  8 hours
SAP Statistical Analy sis Plan
SAR Serious adverse reaction
SOP Standard O perating P rocedure
SUSAR Suspected unexpected serious adverse reaction
T >MIC Time above the minimum inhibitory concentration
TOC Test-of-cure
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 16of 69
1 INTRODUCTION
1.1 Disease characteristics and study drug
1.1.1 Disease characteristics
The incidence of neonatal sepsis isestimated at 2,824 cases per 100,000 livebirths (95% 
CI 1,892–4,194) and is inversel y related to birth weight and gestational age , with a higher 
burden in low -and middle -income countries and a mortality  ranging from 10.3% to 28.6%
(Fleischmann 2021) . Neonatal sepsis may be categori sed as earl y onset (day of life 0 –3) or 
late onset (day of life 4 or later) (Dong 2015). Early-onset sepsis is associated with 
acquisition of infection from the mother , mainly ascending from the cervix, or less 
commonly  via hematogenous or transplacental spread. Late-onset sepsis (LOS) is 
attributed to organisms acquired from the environment ,including coagulase -negative 
staphy lococci (CoNS), Staphylococcus aureus, Enterobacterales, and Pseudomonas
species (Dong 2015, Shane 2017). Empirical antibiotic treatment of LOS is typically  
guided by the antimicrobial resistance patterns of bacterial isolates commonly  detected in 
the neonatal intensiv e care unit or in community  settings. Given the increasing resistance 
among pathogens, alternative antibiotic treatments are needed.
1.1.2 Study drug
Ceftobiprole medocaril2is the water -soluble prodrug of ceftobiprole , an 
advanced- generation intravenous (IV) cephalosporin with bactericidal activity  against a 
broad spectrum of Gram -positive (including CoNS and methicillin -resistant S. aureus
[MRSA] ) and Gram -negative (includi ng Enterobacterales and P. aeruginosa ) pathogens .
Ceftobiprole medocaril is approved for the treatment in adults of hospital -acquired 
pneumonia (excluding ventilator -associated pneumonia) and community -acquired 
pneumonia in many European and non-European countries. It is currentl y under 
investigation to support a New Drug Application in the United States for the treatment in 
adults of acute bacterial skin and skin structure infections (ABSSSI s) and S. aureus
bacter emia , including right -sided infective endocarditis.
In the context of the agreed European Paediatric Investigation Plan, three pediatric clinical 
studies were completed including a study  to evaluate the single -dose safet y and 
pharmacokinetics (PK) of ceftobiprole in neonates and infants up to 3 months of age. The 
purpose of the current study  is to evaluate the safety , PK and efficacy  of ceftobiprole, which 
may be combined with ampicillin and/or an aminogl ycoside, in neonates and infants up to 
3months with LOS.
                                                
2Unless referring specifically to the prodrug, the term ‘ceftobiprole’ is used throughout the remainder of this protocol, 
and all doses are of ceftobiprole equivalents
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 17of 69
1.2 Nonclinical studies with ceftobiprole
A comprehensive summary  of nonclinical studies is provided in the Investigator’s 
Brochure (IB).
1.2.1 Nonclinical pharmacodynamics and activity of ceftobiprole
Dose fractionation studies showed that the time above the minimum inhibitory  
concentration (T>MIC) is the pharmacokinetic -pharmacod ynamic (PK-PD) index that 
correlated best with ceftobiprole activity , which is consistent with the beta -lactam class of 
antibiotics. In a  n eutropenic mouse thigh infection model, the %fT >MIC values 
required for the bacterio static doses were 14 to 28% for S. aureus (including MRSA) and 
Streptococcus pneumoniae , and 36 to 47% for Enterobacterales and P.aeruginosa
(Craig 2008 ).The mean %fT >MIC for the 2-log kill dose for the strains of S. pneumoniae
and S.aureus was 26% and 29%, respectively , while for the strains of Enterobacterales it 
was 65%. Ceftobiprole showe d activities in the lung model similar to those in the thigh 
model .
The probability  of target attainment was estimated by Monte Carlo simulation based on 
data from 150 adult subjects enrolled in Phase 1 and 2 studies analy sed by using population 
PK model ling (Lodise 2007 ). For ceftobiprole 500 mg q8h administered as a 2-hour 
IVinfusion, the probabilit iesof achieving 40% and 60% fT >MIC exceeded 90% for MICs 
< 4 and < 2µg/mL, respectively . The probability  of achieving a nearly  maximal 
bactericidal effect (50% fT >MIC) exceeded 90% for S. aureus (including MRSA) . For 
Gram -negative pathogens, the probability  of achieving a nearl y maximal bactericidal effec t 
(60% fT >MIC) exceeded 90% for non-AmpC- producing isolates. This dose regimen was 
selected for the Phase 3 studies in adults with pneumonia andadults with ABSSSI s.
1.2.2 Nonclinical pharmacokinetics
In animal PK, toxicological, and infection model studies, IV ceftobiprole medocaril was 
rapidly  hydrolyzedin plasma to the active moiety  ceftobiprole by multiple enzy mes,
including plasma esterases ,and also non-enzy matically . The volume of distribution of 
ceftobiprole was restricte d to the extracellular compartment, and its elimination occurred 
predominantly  by passive glomerular filtration of unchanged ceftobiprole. The beta-lactam 
open -ring was the main metabolic product.
In rats, excretion was almost complete within 4days after IV administration of 
ceftobiprole medocaril. Penetration of ceftobiprole into lungs and brain in infected animals 
was demonstrated.
Based on cytochrome P450 inhibition data, the potential of ceftobiprole to exhibit 
clinically relevant drug-drug interactions is small. Protein binding of ceftobiprole in 
plasma of rats, rabbits, marmosets, cynomolgus monkey s, and dogs was low 
(approximately  10% to 45%) and concentration -independent. Plasma protein binding in 
humans was also low (approximately  16%) and concent ration- independent.
Toxicokinetic monitoring during toxicity  studies in rats, rabbits, marmosets, cynomolgus 
monkey s, and dogs demonstrated high and approximately  dose-proportional exposures to 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 18of 69
ceftobiprole in all species, exceeding the expected human therapeutic exposure at the 
no-observed -adverse- effect level (NOAEL). There were no relevant indications of 
accumulation, differences related to sex, or time -dependent PK.
In neonates and juveniles male and female rats administered daily from Day 1 post -partum
until Day 49,which covers the human age range from neonates up to teenagers, 
dose-proportional exposure of the pups and decreased half-life and exposure to ceftobiprole 
with increasing age was demonstrated, as a consequence of increased renal clearance. 
There were no gender -differences. This study  provides a safet y margin of 2 to 6 for 
pediatric patient s (neonates up to < 18 y ears) with the optimized dosing regimens.
1.2.3 Nonclinical toxicology
The toxicological profile of ceftobiprole was characteri sed in an extensive repeated- dose 
toxicity  program that included systemic toxicity  studies up to 13 weeks in rats, dogs and 
primates ;reproductive toxicity ;genotoxicity ;local tolerability ;and special studies to 
address the antigenic, phototoxic and nephrotoxic potential. In addition, juvenile toxicity  
was assessed in rats.
In rats, the primary  targets of toxicity  were the kidney s and the infusion site. Signs of 
vascular irritation at the IV infusion site were likely related to the large size of the catheter 
relati ve to that of the venous lumen. Vascular irritation by the test article was largely 
confined to the region of the vein damaged by  the catheter, with little or no effect distal to 
the infusion site where the vein was exposed to the test article but not to the catheter. 
Toxicity  to the kidney s was observed at doses ≥ 250 mg/kg, and was associated with the 
precipitation of drug-like material in the distal part of the nephron.
In dogs, reddening of the skin and mucous membranes was attributed to histamine relea se. 
No other relevant findings were observed.
In marmosets, thromboembolic effects secondary to infusion site reactions were observed, 
including thrombus formation at the catheter tip. Signs of vascular irritation at the 
IVinfusion site were consistent with respective effects noted in rats, and were likely related 
to technical challenges inherent to chronic IV dosing in small animals. Findings in the 
kidney s were reversible and not associated with microscopic lesions. There were 
noindications of kidney  toxicity  related to precipitation as seen in rats.
Ceftobiprole medocaril was neither teratogenic nor embry otoxic in rats or cynomolgus 
monkey s, and had no effect on fertility  and early  embry onic development in rats. In a 
pre-and post-natal development study in rats, slight maternal toxicity  was seen at high 
doses, but there were no direct effects on pups.
No mutagenic potential was seen in the Ames test or in the Chinese ham ster ovarian assay.
Ceftobiprole medocaril exhibited low irritancy  potential in rabbit local tolerance studies. 
No phototoxic potential was seen, and no hemoly sis or precipitation was observed at 
concentrations ≤ 1.25%.
The toxicity  of ceftobiprole medocaril in neonatal and juvenile rats was investigated in a 
study  with 7-week once daily  subcutaneous administration starting on Day 1 post -partum. 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 19of 69
At the highe st dose of 250mg/kg/day  (187.5 mg/kg/day  ceftobiprole), effects on clinical 
condition and reduced body  weight prior to weaning were seen. Differences in crown to 
rump and bone measurements were considered related to the lower body weight. Gross 
pathological and histopathological changes atthe injection site were noted, and 
microscopic changes in the kidney swere seen at the end of treatment. Based on these 
findings, the NOAEL in juvenile rats was 100 mg/kg/day  (75mg/kg/day  ceftobiprole).
In summary , the nonclinical toxicology  profile of ceftobiprole is consistent with that seen 
with antibiotics of the beta -lactam class, and the observations in juvenile animals were 
similar t o those seen in adult animals.
1.3 Clinical studies with ceftobiprole
The ceftobiprole clinical development program includes 32 completed studies: 21 Phase 1 
studi es in adult subjects, two Phase 1 studies (CSI -1006 and BPR -PIP-001) in pediatric
patients, two Phase 2 studiesin adult patients, fivePhase 3 studies in adult patients, and 
one Phase 3 study  (BPR -PIP-002) in pediatric patients.
One Phase 3 study  (BPR -CS-009) in adult patients with S. aureus bacteremia is currently  
ongoing (Hamed 2020).
1.3.1 Completed Phase 3 clinical studies in adult patients
Table 1gives an overview of key com pleted Phase 3 clinical studies in adult patients.
Table 1Key completed Phase 3 clinical studies in adult patients
Study number /
NCT number
(Reference)Study title Number of patients Study start 
Study end
BAP248/307 /
[STUDY_ID_REMOVED]
(Awad 2014)A Phase 3, randomiz ed, double -blind study of 
ceftobiprole medocaril versus linezolid plus 
ceftazidime in the treatment of nosocomial 
pneumoniaN=781
Ceftobiprole (n=391) 
Comparator (n=390)06 Apr 2005 
22May 2007
CAP -3001 /
[STUDY_ID_REMOVED]
(Nicholson 2012)Randomized, double- blind, multicenter study of 
ceftobiprole medocaril versus ceftriaxone 
with/ without linezolid in treatment of subjects 
hospitali sed with community -acquired 
pneumoniaN=638
Ceftobiprole (n=314) 
Comparator (n=324)05 Jun 2006 
19 Jul 2007
BPR -CS-008/
[STUDY_ID_REMOVED]
(Overcash 2021)A randomi zed, double -blind, multicenter study to 
establish the safety and efficacy of ceftobiprole 
medocaril compared w ith vancomycin plus 
aztreonam in the treatment of acute bacterial ski n 
and skin structure infectionsN=679
Ceftobiprole (n=335) 
Com parator (n=344)19Feb 2018 
22Apr 2019
In studies BAP248/307, CAP -3001, and BPR-CS -008, ceftobiprole was administered as a 2-hour 500 mg IV infusion 
every 8 hours.
In all completed Phase 3 studies in adult patients, the non-inferiority  of ceftobiprole to 
comparator antibiotics was demonstrated within the pre-specified non- inferiority  margin 
for the primary  efficacy  endpoint in each study .
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 20of 69
Safety  findings in the ceftobiprole clinical development program are consistent with the 
cephalosporin class effects and the underl ying disease. Overall, treatment with ceftobiprole 
is well tolerated, with a manageable AE profile.
1.3.2 Completed studies in p ediatric patients
Table 2outlines completed clinical studies in pediatric patients.
Table 2Completed clinical studies in ped iatric patients
Study number / 
NCT number
(Reference)Study title Phase Number of patients Study start
Study end
CSI-1006 / 
[STUDY_ID_REMOVED]
(Rubino 2021a )An open -label study to evaluate the 
single -dose pharmacokinetics and safety 
of cefto biprole in pediatric subjects ≥ 3 
months to < 18 years of age undergoing 
treatment with systemic antibiotics1 N=64 08Nov 2007 
02 Apr 2010
BPR -PIP-001 / 
[STUDY_ID_REMOVED]
(Rubino 2021 b)An open -label study to evaluate the 
single -dose pharmacokinetics and safety 
of ceftobiprole in neonate and infant 
patients aged up to 3 months undergoing 
treatment with systemic antibiotics1 N=15 22Nov 2016 
07 Jul 2020
BPR -PIP-002 / 
[STUDY_ID_REMOVED]
(Bosheva 2021)A multicenter, randomi zed, Investigator -
blind, active -controlled study to evaluate 
the safety, tolerability, pharmacokinetics 
and efficacy of ceftobiprole versus 
intravenous standard -of-care 
cephalosporin treatment with or without 
vancomycin in pediatric patients aged 
from 3 months to less than 18 years with 
hospital -acquired pneumonia or 
community -acquired pneumonia 
requiring hospitali sation3 N=138 
Ceftobiprole (n=94) 
Com parator (n=44)27Nov 2017 
16Mar 2020
1.3.2.1 Study CSI-1006
The primary  objective of study  CSI-1006 was to characteri sethe PK of ceftobiprole when 
administered as a 2-hour single -dose infusion in pediatric patients aged ≥ 3 months to 
< 18 years,who required therapeutic or proph ylactic therap y with systemic antibiotics. The 
secondary  objective was to evaluate the safet y and tolerability of ceftobiprole in this study  
population.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 21of 69
This was a multicent er, open -label, single -dose, Phase 1 study  thatenrolled 64 pediatric
patients in the following four age groups with documented or presumed, or at risk for, 
bacterial infections, and receiving s ystemic antibiotic therap y:
3 months to < 2 years (18 patients, 15 mg/kg)
2 years to < 6 years (15 patients, 15 mg/kg)
6 years to < 12 years (15 patients, 10 mg/kg)
12 years to < 18 years (16 patients, 7 mg/kg)
1.3.2.1.1 Pharmacokinetic results
Of the 62 patients who completed the study , 61 were included in the descriptive statistics 
of the ceftobiprole plasma concentrations, and 55 were included in the estimation of the 
plasma PK and exploratory  PD parameters.
Overall, at the doses administered to patients aged < 12 years (15mg/kg for patients aged 
< 6years and 10mg/kg for patients aged 6 years to < 12 years), the single -dose PK were 
generall y within the range of what was previousl y observed in healthy  adult subjects after 
a single ceftobiprole 500 mg dose. At the dose administered to patients aged 12 years to 
< 18 years (7mg/kg, up to a maximum of 500mg), the systemic exposure was substantially 
lower than that achieved in adults after a single ceftobiprole 500 mg dose.
1.3.2.1.2 Safety results
The safet y assessments in this pediatric study  showed that single -dose administration of 
ceftobiprole was safe and well tolerated by patients aged ≥ 3 months to < 18 years. No new 
or unexpected safety  signals associated with ceftobiprole were detected .
1.3.2.2 Study BPR -PIP-001
The primary  objective of study  BPR-PIP-001 was to characteri se the PK of ceftobiprole 
when administered as a 4-hour single-dose (7.5mg/kg )infusion in neonates and infants 
aged ≤ 3 months. The secondary  objective was to evaluate the safety and tolerability  of 
ceftobiprole in this study  population.
This was a multicenter, open -label, single -dose, Phase 1 study  that planned to enroll 
45 patients who had documented, or were presumed to be at risk of, bacterial infections, 
and who were alread y receiving systemic antibiotic therap y. This study  enrolled 15 term 
neonates (gestational age ≥37 weeks).
1.3.2.2.1 Pharmacokinetic results
While all 15 patients enrolled in the study  had measurable plasma concentrations, 
twopatients had insufficient PK data for the non-compartmental analy sis, and were 
therefore excluded from the PK anal ysis population.
Overall, exposure to the active moiety  ceftobiprole was substantially  higher than that for 
the prodrug ceftobiprole medocaril and the open -ring metabolite. The median maximum 
plasma concentration (Cmax)was highest for ceftobiprole (11.2 μg/mL) compared to 
ceftobiprole medocaril (0.107 μg/mL) and the open -ring metabolite (0.644 μg/mL). 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 22of 69
Ceftobiprole time to maximum concentration was reached at the end of infusion (i.e., at 
4hours )in all patients.
1.3.2.2.2 Safety results
The safet y assessments in this pediatric study  showed that single -dose administration of 
ceftobiprole at 7.5 mg/kg was safe and well tolerated b y the neona te and infant population 
aged ≤ 3 months. No new or unexpected safet y signals associated with ceftobiprole were 
detected.
1.3.2.3 Study BPR -PIP-002
The primary  objective of study  BPR-PIP-002 was to evaluate the safety  profile of 
ceftobiprole in pediatric patients aged 3months to < 18 years with hospital -acquired 
bacterial pneumonia (HABP) or community -acquired bacterial pneumonia (CABP )
requiring hospitali sation and IV antibiotic therap y.
The secondary  objectives were to characteri se the PK of ceftobiprole and to evaluate the
efficacy  of ceftobiprole versus IV standard -of-care cephalosporin treatment 
(±vancom ycin) in this patient population .
This was a multicenter, randomi zed(2:1) , Investigator- blind, active -controlled study  that 
enrolled 138 patients (94 in the ceftobiprole group and 44 inthe comparator group).
Patients randomi zed to ceftobiprole received IV infusions every  8hours (q8h) at 
ageadjusted doses and infusion durations as follows:
3 months to < 2 years (12 pati ents, 20mg/kg as 4-hour infusions)
2 years to < 6 years (37 patients, 20mg/kg as 2- hour infusions )
6 years to < 12 years (27 patients, 15mg/kg as 2- hour infusions )
12 years to < 18 years (18 patients, 10mg/kg as 2 -hour infusions)
1.3.2.3.1 Pharmacokinetic results
The PK population comprised 33 patients who received atleast one dose of ceftobiprole 
and had at least one ceftobiprole plasma concentration measurement obtained. Of these, 
plasma concentration -time data were available for 29 patients. Exposure to ceftobiprole 
was substantially  higher than that for the prodru g ceftobiprole medocaril and the open -ring 
metabolite. Ceftobiprole peaked at the end of infusion (4 hours for patients < 2years and 
2 hours for all other age groups).
In general, patients under 6 years of age (i.e., those who received ceftobiprole 20 mg/kg 
q8h) had higher ceftobiprole exposure and slightly  longer half-life compared to patients 
aged 6 years or older. Mean Cmaxand area under the plasma concentration -time curve 
time zero to tau estimates were ~40% greater and half-life was ~16% longer in patients 
aged under 6 years compared to those 6 years or older (Cmax: 33.3 versus 23.7 µg/mL ;
AUC tau: 108 versus 77.6 h.µg/mL , respectively ).
1.3.2.3.2 Safety results
The safet y and tolerability  of ceftobiprole in this study  were consistent with the established 
safet y profile for ceftobiprole in adults and with thoseof the cephalosporin class of 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 23of 69
antibiotics. No new or unexpected safet y signals associated with ceftobiprole were 
detected.
1.3.2.3.3 Efficacy results
Although the stud y wasnot powered to compare efficacy, this was the onl y pediatric study  
to-date that included efficacy  objective s. The early  clinical response rate at Day 4 w as 
slightly  higher in the ceftobiprole group than in the comparator group for both the 
intent -to-treat (ITT)and Clinically  Evaluable (CE)populations, and at the test-of-cure 
(TOC ) visit, the clinical cure rate was above 90% in both treatment groups, although lower 
in the ceftobiprole group than in the comparator group for both populations.
1.3.3 Benefit -risk assessment
Data from the clinical studies show that ceftobiprole can be safel y administered to adult 
and pediatric (neonates to < 18 years of age) patients. Completed Phase 3 studies 
demonstrated the safety  and efficacy  of ceftobiprole in the adult population for various 
indications (HABP , CABP , and ABSSSI ),and in the pediatric population the safet y and 
efficacy  in patients with bacterial pneumonia were similar to those observed in adult 
patients. One Phase 3 study  is currently  ongoing to evaluate the safet y and efficacy  of 
ceftobiprole for the treatment of S. aureus bacter emia in adult patients.
The potential benefit to patients participating in this study  is receiving antibiotic therapy  
for their infection, and the potential benefit of this study  in general is the identification of 
a new addition to the available antibiotic therapy  that is safe and effective for the treatment 
ofLOS. It is possible that ceftobiprole will not prove to be a sufficientl y effective treatment 
for LOS. This risk is mitiga ted by the optional addition of ampicillin and/or an 
aminogl ycoside, by close monitoring of study patients, and by management with 
appropriate therapies as determined by the Investigator. The risk considerations for this 
study  encompass the known and potential risks for ceftobiprole , as well as those risks 
associated with other treatments that may be administered (i.e., ampicillin and/or an 
aminogl ycoside) as described in their respective prescribing information.
1.4 Study rationale
This study  is part of a pediatric clinical development program to evaluate the use of 
ceftobiprole in patients < 18 years of age. Three completed pediatric studies , two Phase 1 
and one Phase 3,are described in Section 1.3.2. Study  BPR-PIP-001 assessed the PK and 
safet y of single -dose ceftobiprole in t erm neonates and infants aged ≤3 months.
LOS is a major cause of morbidity  and mortality  among neonates and young infants. 
Pathogens responsible for LOS include CoNS, S. aureus , Enterobacterales, and 
P.aeruginosa. C eftobiprole hasa broad -spectrum bactericidal activity  against most of
these organisms , and was well tolerated in adult and pediatric clinical studies with a saf ety
profile consistent with that of available cephalosporins. Therefore ,ceftobiprole has the
potential to become a therapeutic option in the treatment of LOS .
The purpose of this study  is to assess the safet y, tolerability , PK, and clinical effect of 
ceftobiprole, possibl y combined with ampicillin and/or an aminogl ycoside, in neonates and 
young infants up to 3 months of age with LOS.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 24of 69
1.4.1 Summary of study design
This is a multicent er, open -label, single -arm, multiple -dose study  of IV ceftobiprole in term 
and pre-term neonates and infants up to 3 months of age with LOS. Ceftobiprole may be 
combined with ampicillin and/or an aminogl ycoside based on the Investigator’s judgement , 
local standard of care,and/or isolated or presumed pathogens. At least eight patients, at 
least twoterm (gestational age ≥ 37 weeks) and at least six pre-term (gestational age ≥ 24 
to 36 weeks), wit h post -natal age ranging from ≥ 3 day s to ≤3 months will be enrolled.
The DSMB will review data on a regular basis to assess the safety  of all patients enrolled 
in this study (see Section 3.4).
1.4.2 Study design rationale
A single -arm study  design is based on practical considerations, mainl y the feasibility  of 
recruitment and study  evaluation of pre-term and term neonates and young infants with 
LOS. As the incidence of LOS is inversel y proportional to gestational age (i.e., almost 
double in pre-term neonates ≤ 32 weeks as compared to term neonates [Dong 2015]), twice 
as many  pre-term neonates than term neonates will be enrolled.
Immediate administration of empiric antibiotic therap y with broad -spectrum bactericidal 
activity  is critical in neonates and young infants with LOS, in order toprevent morbidity 
and decrease mortality . The optional combination with ceftobiprole of ampicillin and/or an 
aminogl ycoside allows for maximal coverage of Gram -positive and Gram -negative 
pathogens of LOS , particularl y during initial empiric treatment, andin accordance with 
local pathogen epidemiology  and local standard of care .
1.4.3 Dose rationale
A three -compartment pediatric population PK model with linear elimination, clearance 
dependent on glomerular filtration, and other PK parameters scaled to body  weight using 
a fitted coefficient consistent with allometric scaling principles, provided a robust fit to 
pooled data from studies CSI-1006, BPR -PIP-001, and BPR -PIP-002. Pre-defined model 
qualification procedures indicated that the final population PK model was expected to 
provide reliable estimates of ceftobiprole plasma exposure in the pediatric patients enrolled 
in these studies, and that the model was appropriate for the conduct of model -based 
simulations designed to identify  appropriate ceftobiprole dosing regimens in pediatric 
patients ( Rubino 2021a ).
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 25of 69
Model -based simulation analyses conducted using the final population PK model suggest 
that the following dosing regimens are predicted to result in consistent ceftobiprole 
exposure and adequate PK -PD target attainment for pathogens with a ceftobiprole MI C of 
4 µg/mL (≥97.1% of the pediatric population with a %fT>M IC above 40%):
ceftobiprole 10 mg/kg infused over 2 hours and administered q12h in neonates and 
infants aged < 3 months with a body  weight < 4 kg
ceftobiprole 15 mg/kg infused over 2 hours and administered q12h in neonates and 
infants aged < 3 months with a body  weight ≥ 4 kg
ceftobiprole 15 mg/kg infused over 2 hours and administered q8h in infants and 
children aged ≥ 3 months to < 12 y ears with a body  weight < 33 kg 
ceftobiprole 10 mg/kg infused over 2 hours and administered q8h inadolescents aged 
≥ 12 to < 18 y ears with a body  weigh t < 50 kg 
ceftobiprole 500 mg infused over 2 hours and administered q8h in children with a body  
weight ≥ 33 kg and adolescents with a body  weight ≥ 50 kg
Model -based simulations also indicated that the dose should be adjusted based on bod y 
weight or maxim um allowable dose to avoid overly  high exposures in the lightest infants 
(< 4 kg), children ≥ 33 kg, and adolescents ≥ 50 kg.
Extrapolation of the model to pre-term neonates and young infants was deemed appropriate 
given the dependence of ceftobiprole PK on glomerular filtration rate and body  weight, 
which are both well described in this population. Glomerular filtration rate was assigned 
using a standard equation that assumed normal renal function, adjusted for age and body 
surface area using fat-free mass (Rhodin 2009). Body weight and height were assigned 
using a set of polynomial longitudinal growth equations, which define body  weight and 
height over time based on gender, gestational age, and post -natal age (Troutman 2018).
Model -based simulation analyses to assist in the ceftobiprole dose selection for the 
treatment of LOS in pre-term and term neonates and young infants assessed several dose 
regimens before identification of an optimal regimen (Table 5). The optimal dose regimen, 
with dose adjustment according to gestational and post -natal ages, was predicted to result 
in a consistent ceftobiprole exposure and adequate PK-PD target attainment similar to those 
in adults and older pediatric patients. In general, the median predicted AUC0 –24 values 
fall within the mean two standard deviations from the adult Phase 1 exposures from the 
multiple -ascending dose study . The 90% prediction intervals fall outside the range but 
remain acceptable. In contrast, ceftobiprole Cmax estimates were predicted to be lower 
than those observed in healthy  adults, with the exception of the patients in the oldest 
gestational age group ( ≥ 37 weeks), which are similar to adults.
2 OBJECTIVES OF THE STU DY
2.1 Primary objective
To charact erise the safet y profile of ceftobiprole in term and pre -term neonates and infants 
up to 3 months of age with L OS.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 26of 69
2.2 Secondary objectives
To assess in term and pre-term neonates and infants up to 3 months of age with LOS treated 
with ceftobiprole:
PK of ceftobiprole
Clinical response
All-cause mortalit y
Microbiological response
3 STUDY DESIGN
This is a multicenter, open -label, single -arm, multiple -dose study  of IV ceftobiprole in term 
and pre -term neonates and infants up to 3 months of age with LOS. At least eight patients, 
at least two term (gestational age ≥ 37 weeks) and at least six pre-term (gestational age 
≥ 24 to 36 weeks), with post-natal age ranging from ≥ 3 days to ≤ 3 months will be enrolled
at approximately tensites in Europe and USA, with additional sites and locations possible .
Study  therap y consists of IV ceftobiprole medocaril for 3–10 days, which may be extended 
to 14 days if considered clinically  necessary  by the Investigator. Ceftobiprole may be 
combined with ampicillin and/or an aminogl ycoside based on the Investigator’s judgement , 
local standard of care,and/or isolated or presumed pathogens. If added, the treatment 
duration of ampicillin and/or an aminogl ycoside is at the discretion of the I nvestigator.
Each patient is expected to complete the study  in approximately  5–7weeks, including 
screening, an estimated treatment duration of 3–10 days with possible extension up to 
14days, end-of-treatment (EOT) visit, TOC visit 7–14 days after last ceftobiprole dose, 
and a last follow- up (LFU) visit 28 –35days after last ceftobiprole dose.
Safety  assessments will be done throughout the study . Specimens for microbiological 
assessment will be obtained as clinicall y indicated in accordance with local standard of 
care. Blood samples for PK anal ysis will be collected on Day  3. Efficacy  outcomes will be 
assessed at the EOT, TOC, and LFU visits.
The DSMB will review data on a regular basis to assess the safety  of all patients enrolled 
in this study  (see Section 3.4).
3.1 Overview of study design and dosing regimen
An overview of the stud y design is provided in Figure 1.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 28of 69
3.2 Endpoints
3.2.1 Primary endpoint
The primary  endpoint is safety and tolerability in the Safety  population , as assessed by 
AEs, SAEs , deaths, and discontinuations due to AEs during treatment with ceftobiprole 
and at the EOT, TOC, and LFU visits, as well as clinical laboratory  tests, vital signs, and 
physical examination findings .
3.2.2 Secondary endpoint s
Pharmacokinetics
Plasma levels of ceftobiprole, ceftobiprole medocaril, and the open -ring metabolite in 
the PK population
Efficacy
Clinical cure rate at the EOT and TOC visits (ITT and CE populations)
All-cause mortalit y through Day  28(ITT population)
Microbiological eradication or presumed eradication rate at the EOT and TOC visits
(mITT and ME populations)
Improved signs and symptoms of LOS at the Day 3, EOT, and TOC visits (ITT and 
CEpopulations)
3.3 Treatment plan
3.3.1 Dose modifications
The intended dose of IV ceftobiprole may not be modified. As patients with moderate or 
severe renal impairment will be excluded, no need for dose adjustment is expected. Study 
drug may be discontinued at an y time at the Investigator’s discretion (see Secti on 4.4). If a 
patient’s estimated glomerular filtration rate (using the Schwartz formula or other 
applicable formula) decreases to less than two-thirdsof normal for the applicable age 
group ,or urinary  output decreases to < 0.5 mL/kg/h (measured over at least 8hours) during 
study  drug treatment, ceftobiprole administration should be stopped and the patient should 
be switched to standard of care treatment. If continuation of ceftobiprole is considered 
necessary  by the Investigator based on an individual medical benefit -risk assessment for a 
patient, then the implementation of real-time plasma level assessments of ceftobiprole is 
recommended.
If added, any dose modification for ampicillin and/or an aminogl ycoside is at the discretion 
of the Investigator in accordance with local standard of care; aminogly coside dose 
modification may  be based on renal function or therapeutic drug monitoring .
3.3.2 Duration of treatment
The target treatment duration with IV ceftobiprole (administered as a 2-hour IV infusion 
according to the schedule inTable 5)is 3–10 days, which may be extended to 14 days if 
considered clinically  necessary  by the Investigator.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 29of 69
If added, the treatment duration of ampicillin and/or an aminogl ycoside is at the discretion 
of the Investigator in accordance with local standard of care.
3.3.3 Missed -dose management
If one or more doses of IV ceftobiprole are missed, no additional doses are to be 
administered other than in accordance with the schedule provided inTable 5. In such cases, 
the Investigator may  consider exclusion of the patient from the stud y after discussion with 
the medical monitor.
For ampicillin and/or an aminogl ycoside, if added, management of missed doses is at the 
discretion of the Investigator in accordance with local standard of care.
3.3.4 Overdose
There is no available information on overdose with ceftobiprole in humans. The highest 
daily  dose administered in Phase 1 clinical studies in adult s was 3 ,000 m g (1,000 m g q8h). 
The range ofdosesadministered in the Phase 1 pediatric study  BPR -PIP-001was 17.6 to 
37.5 mg (5.8 to 7.5 mg/kg) in neonates and infants aged ≤ 3 months.
If an overdose occurs, it should be treated symptomatically .Symptomatic treatment may
include treatment of gastrointestinal or central -nervous -system side effects 
(e.g., convulsions) which may be related to peak ceftobiprole plasma concentrations. 
Monitoring of plasma levels of ceftobiprole should therefore be considered. Ceftobiprole 
half-life is approximately  3.5 hours and plasma concentrations can be reduced by 
haemodial ysis.
For ampicillin and/or an aminogl ycoside, if added, see the respective local labels.
3.4 Data and Safety Monitoring Board
The composition, roles and responsibilities, and schedule of data review meeting of the 
DSMB are described in the DSMB Charter. The DSMB will review patient data on an 
ongoing basis to determine whether any safet y concerns are observed, and whether the 
study  should be allowed to continue.
3.5 Definition of the end of the study
The end of the study  is defined as the completion of the last study -related contact with the 
last participant in the study .
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 30of 69
4 STUDY POPULATION
4.1 Target population
Term (gestational age ≥ 37 weeks) and pre-term (gestational age ≥24 to 36weeks) 
neonates and infants, with post -natal age ranging from ≥3 days to ≤3 months, meeting all 
of the inclusion criteria and none of the exclusion criteria are eligible for enrol lment in this 
study .
4.2 Inclusion criteria
For inclusion in the study, patient s must meet allof the following criteria :
1.Informed consent from parent(s) or other legally -acceptable representative (LAR) to 
participate in the stud y
2.Male or female, with a gestational age of ≥24 weeks and a post-natal age ranging from 
≥ 3days to ≤ 3months
3.Diagnosis of documented or presumed bacterial LOS requiring administration of IV
antibiotic treatment. 
Patients must present with at least twoof the clinical criteria and at least oneof the 
laboratory  criteria listed below :
Clinical criteria (at least two):
a)Hypothermia (< 36.6 °C/ 97.9 °F rectal; < 36.5 °C/ 97.7 °F axillary ; 
< 35.5 °C/ 95.9 °F oral; < 35.8 °C/ 96.4 °F ty mpanic) OR feve r 
(>38.0 °C/ 100.4 °F rectal; > 37.5 °C/ 99.5 °F axillary ; >37.5 °C/ 99.5 °F oral; 
> 38.0 °C/ 100.4 °F ty mpanic)
b)Brad ycardia (< 100 beats/minute awake; < 80 beats/minute asleep) OR 
tachycardia (> 205 beats/minute awake; > 160 beats/minute asleep)
c)Urinaryoutput 0.5–1 mL/kg/h OR hy potension OR signs of impaired peripheral 
perfusion, such as mottled skin, moist and cold skin, finger to forearm 
temperature gradient, or increased capillary  refill time
d)Petechial rash OR sclerema neonatorum
e)New onset or worsening of apn eaepisodes OR tachy pnea episodes OR increased 
oxygen requirements OR requirement for ventilatory support (excluding 
underly ing ventilator -associated pneumonia; see exclusion criteria)
f)Feeding intolerance OR poor sucking OR abd ominal distension
g)Irritability
h)Lethargy
i)Muscular hypotonia
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 31of 69
Laboratory criteria (at least one):
a)White blood cell count ≤ 4.0 × 109/L OR ≥ 20.0 × 109/L
b)Immature to total neutrophil ratio > 0.2
c)Platelet count ≤ 100 × 109/L
d) C- reactive protein > 15 mg/L OR procalcitonin ≥ 2 ng/mL OR Interleukin-6
(IL-6) elevated according to local laboratory  thresholds
e)Hypergl ycemia OR hypogl ycemia
f)Metabolic acidosis
4.Sufficient vascular access to receive study  drug and to allow blood sampling at a site
separate from the stud ydrug infusion line
4.3 Exclusion criteria
Patient s who meet anyof the following criteria must be excluded from the study :
1.History  of a previous clinically  relevant h ypersensitivity  or serious adverse reaction
to beta -lactam antibiotics, or to aminogl ycosides if intended to be used in
combination with ceftobiprole
2.Viral, fungal , or parasitic pathogen as the sole reason for infection, OR known
resistance of the causative bacterial pathogens to ceftobiprole
3.Refractory  septic shock not responding to 60 minutes of vasopressor treatment within
48 hours before enrollment
4.Proven ventilator -associated pneumonia
5.Proven central nervous system infection (e.g., meningitis, brain abscess)
6.Proven osteomy elitis, infective endocarditis, or necrotis ing enterocolitis
7.Impaired renal function or known significant renal disease, as evidenced b y an
estimated glomerular filtration rate (using the Schwartz formula or other applicable
formula) calculated to be less than 2/3 of normal for the applicable age group, OR
urinary  output < 0.5mL/kg/h (measured over at least 8 h ours), OR requirement for
dialy sis
8.Significant laboratory  abnormalities, including:
a)Hematocrit <20%
b)Absolute neutrophil count < 0.5 × 109/L
c)Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 8 ×the
age-specific upper limit of normal
9.Progressively  fatal underly ing disease, or life expectancy < 30 days
10.Documented history  of convulsions
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 32of 69
11.Severe immunodeficiency  (congenital or acquired)
12.Use of s ystemic anti bacterial therap y for longer than 72hours within 7 days before
start of study  medication
13.Any condition including antepartum / peripartum factors or procedures, which would, 
in the opinion of the I nvestigator, make the patient or caregiver unsuitable for the 
study , putting the patient at risk or compromising the quality  of the data
14. Particip ation in another clinical study  with an investigational product within 30 day s 
of enrollment in the current study
4.4 Patient wi thdraw al
Parents or LAR smay voluntarily  withdraw consent for the patient’s participation inthe 
study  at any time for any reason. The Investigator may also withdraw a patient from the 
study for reasons which may include adverse reactions (including but not limited to 
allergic -type reactions, infusion site reactions, or clinically  relevant changes in vital signs), 
apparent infant distress, or at the request of the parent or theLAR .
If patients are withdrawn, the date of withdrawal and the reason for withdrawal must be 
recorded in the electronic case report form ( eCRF ).
If a patient who has received at least onedose of study drug discontinues treatment at any  
time for reasons other than withdrawal of consent , every  effort must be made to complete 
the E OT and LFU visit s.
Reasons for discontinuation of study  treatment must be recorded, and may  include:
Adverse event
Abnormal laboratory  value
Abnormal test procedure result
Intercurrent illness that prevents furt her administration of treatment
Diagnosis of any of the following conditions after enrollment in the study : 
ventilator -associated pneumonia, meningitis, brain abscess, osteom yelitis, infective 
endocarditis, or necrotis ing enterocolitis
Confirmation of reduced susceptibility  to ceftobiprole of an y pathogen isolate d
Death
Withdrawal of consent
Withdrawn from the s tudy at the Investigator ’sdiscretion
Protocol deviation /non- compliance
Lost to follow -up
Administrative reasons
The reasons for discontinuation of study treatment must be recorded in the eCRF.
For allpatients who discontinue study  treatment, AE monitoring must be continued up to 
and including the LFU visit. For patients who fail to return for the LFU visit, the 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 33of 69
Investigator must make every  effort to contact the pa rent(s)or LAR (by telephone or mail 
correspondence). The outcome of this con tact must be documented b y the Investigator and 
filed in the Investigat orSite File (ISF) .
4.5 Replacement of patients
Patients failing screening procedures are to be replaced.
Patients who for any reason discontinue participation in the study  after enrollment but prior 
to receiving the first dose of study  drug are to be replaced.
Patients who for any reason discontinue participation in the study  after receiving the first 
dose of study  drug are not to be replaced.
4.6 Study discontinuation
The Sponsor reserves the right to temporarily  or permanentl y discontinue the study  at any 
time. Reasons for study  discontinuation may  include, but are not limited to:
Safety  concerns (an identified risk or potential risk that could have an impact on the
benefit -risk balance of the product or implications for public health).
Poor enrollment.
Non-compliance with the protocol, Good Clinical Practice (GCP) guidelines, or other
regulatory  requirements by  the Investigator(s).
Request to discontinue the study  by a Health Authority .
Enroll ment to either study  group (term or pre -term) will be discontinued after the
minimum number of patients to the group is reached. Enrollment to the other group will
continue until the minimum required number of patients is also reached.
The Sponsor will ensure that all Investigators and the appropriate Health Authorities are 
promptly  informed if the study  is suspended or terminated prematurel y for safet y reasons. 
In the event of such a termination, the Investigator will also promptly  notify  the IEC/IRB.
5 SCHEDULE OF ASSE SSMENTS AND PROCEDURES
5.1 Summary of schedule of assessments
Table 3presents a summary  of the schedule of assessments to be performed from screening 
through the LFU visit.
Adverse events will be monitored on an ongoing basis and at each study  visit, beginning 
on study  Day 1. Adverse event monitoring must be continued up to the LFU visit
(seeSection 7.4).
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 34of 69
Table 3Schedule of assessments
Visit name Screening /
BaselineActive treatm ent
(Days 1, 2, 3, 4 10, and, if applicable, 11–14)1EOT2TOC LFU3
Assessment window Day −2 to
Day 1Day 1 Day 2 Day 3 Days 
410Days 11 14,
only if 
applicableWithin 24 h
after
last dose7–14
days
after
last dose28–35
days
after
last dose
Written informed consent4X
Inclusion/exclusion criteria X
Medical history and demographics (including 
antepartum/peripartum period)X
Prior medications5X
Physical examination6X X6X X
Length X
Weight7X X7X X X X X X
Vital signs and pulse oximetry8X X8X8X8X8X8X X
Signs and symptoms of LOS X X X X X X X X
Hem atology, blood chemistry, urinalysis9X X9X X9
Anion gap, C -reactive protein, procalcitonin , 
IL-6(optional )10X10X10
Urine output11X11X11
Imaging tests (optional)12X12X12
Microbiological sampling13X13X13
Overall clinical outcome assessment14X X
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 35of 69
Microbiological outcome assessment15X X
Study drug administration1X X X X X1
Concomitant medications16X X X X X X X X
Concomitant medical procedures X X X X X X X X
Adverse event assessment17X X X X X X X X
PK blood sampling18X
Aminoglycoside monitoring, if applicable19X19
Survival status20X
Relapse assessment X
EOT =end of treatment; LFU =last follow -up; LOS =late-onset sepsis; PK =pharmacokinetics; TOC =test of cure.
1The duration of treatment with ceftobiprole (i.e., study drug) is 3–10 days, but this may be extended to 14 days if considered clinically necessary by the Investigator if in accordance 
with local standard of care (see Section 3.3.2 ).The duration of treatment with ampicillin and/or an aminoglycoside antibiotic, if given in combination with ceftobiprole, is atthe 
Investigator’s judgment in accordance with local standard of care (i.e., may be terminated at any time if considered appropriate by the Investigator) and must be recorded .16
2EOT assessment is to be performed on the day of last study drug administration, or as a separate visit within 24 hours of last study -drug administration . 
3The LFU visit may be performed by telephone contact if the patient has been discharged from the hospital , unless an examination is needed to evaluate relapse or abnormalities 
recorded during the TOC visit (see Section 5.2.5 ).
4Written informed consent (or, in the event of an emergency, verbal informed consent followed by written consent as soon as the situation allows) must be obtained before any 
study -specific procedures or assessments take place (see Section 10.2).
5Prior medications taken within 7 days before the first dose of study drug is to be recorded. For patients who are being breastfed, all medications taken by the lactating mother within 
3days before the first dose of study drug is to be recorded.
6Complete physical examination is to be performed at Screening, the EOT visit, and the TOC visit. Complete or targeted physical examinations focusing on changes f rom baseline 
is to be performed during the active treatm ent period at the discretion of the Investigator as clinically indicated in accordance with local standard of care (see Section 5.5.2 ).
7Body weight on Day 1, which is tobe used for Day 1 dose calculation, should be obtained within 12hours prior to the first dose of study drug. From Day 2 until the last day of 
study treatment, the dose should be calculated based on the patient’s first bod y weight of the day (see Section 5.5.2 ).
8Vital signs (including body temperature, respiratory rate, pulse rate, and systolic and diastolic blood pre ssures) and pulse oximetry must be recorded within 30 minutes before the 
first study drug administration , and then three times daily during the active treatment period; if continuously monitored, the highest body temperature, respiratory rate, and pulse 
rate, and the lowest systolic and diastolic blood pressures and oxygen saturation obtained during an 8 -hour period, are to be recorded. Vital signs and pulse oximetry must also be 
obtained at the EOT and the TOC visits (see Section 5.5.3 ).
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 36of 69
9Hematology, blood chemistry, and urinalysis are to be performed at baseline and at the EOT visit. At all other visits, these laboratory evaluations are to be perform ed only if 
clinically indicated based on the Investigator’s judgment in accordance with local standard of care (for details, see Sections 5.2.2 , 5.2.4 , and 5.5.4 ).
10Optional assessment of anion gap, C -reactive protein, procalcitonin, and IL-6 at any time from Screening until the end of active treatment, if considered clinically indicated by the 
Investigator in accordance with local standard of care.
11If clinically indicated, measurement of u rine output should be done over at least an 8 -hour period. Use of a urinary catheter is based on the Investigator’s judgment in accordance 
with local standard of care. Urinary catheters are not required for the purposes of this study (see Sections 5.2.1 , 5.2.2 ).
12Results of imaging tests (e. g., chest X -ray, ultrasound, CT scan, MRI) performed as part of the patient’s standard clinical care within 72 hours before start of study treatment are to
be recorded in the eCRF. From Day 1 up to and including the TOC visit, imaging tests are to be perfo rmed if clinically indicated based on the Investigator’s judgment in accordance 
with local standard of care.
13Screening/ baseline and post-baseline blood specimens and any other specimen s (e.g., urine, cerebrospinal fluid) for microbiological evaluation should be obtained as clinically  
indicated in accordance with local standard of care and as described in the Laboratory Manual.
14At the EOT and TOC visits, the Investigator must rate the overall clinical outcome as ‘clinical cure ’, ‘clinical failure’, or ‘u nevaluable ’.
15Microbiological outcome is to be assessed only in patients with valid pathogens identified at the Screening/Baseline visit.  For details, see Section 5.6.3 .
16All medications taken after the recording of prior medications, and medications continued after enrollment in the study, should be recorded as concomitan t therapy. For patients  
who are being breastfed ,all concomitant medications taken by the lactating mother up to the LFU visit are to be recorded.
17See Section 7.4.
18PK blood sampling is tobe done on treatment Day 3as described in the Laboratory Manual : pre-dose before the first ceftobiprole infusion, at 2hours (end of infusion), 4hours, 
and 8 hours. PK samples should not be taken from the infusion lines. See Section 5.7.
19In the event of combination treatment with an aminoglycoside, monitoring of aminoglycoside blood levels and monitoring for ototoxicity and/or nephrotoxicity should be performed 
according to r ecommendations in the local label and local standard of care.
20Survival status is to be assessed.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 37of 69
5.2 Study visits
Parent (s)or a LAR must provide written informed consent before any study -specific 
assessments or procedures are performed (see Section 10.2 for details) .
5.2.1 Screening visit / Baseline ( Day −2 to Day 1 )
The following assessments and procedures will be performed at the screening visit (Day −2
to Day  1;seeTable 3):
Medical history  and demographics, including theantepartum/peripartum period
(seeSection 5.3.1)
Review and recording of medication s taken within 7daysbefore the first dose of study
drug. For patients who are being breastfed, medications taken by the lactating mother
within 3 days bef ore the first dose of study  drug will also be recorded.
Physical examination (see Section 5.5.2)
Length and body weight (see Section 5.5.2)
Vital signs (including body  temperature, respiratory  rate, pulse rate, and systolic and
diastolic blood pressure s) and pulse oximetry (see S ection 5.5.3)
Signs and s ymptoms of LOS (see Section 5.6.4)
Local laboratory  tests: result s will be used for the assessment of inclusion/exclusion
criteria and throughout the study  (for details ,see Sections 4.2, 4.3, and 5.5.4).
Laboratory  tests required as part of the screening process which have been performed
within 48hours prior to the first dose of study drug do not need to be repeated,
regardless of whether they were performed before or after signing of the informed
consent form (ICF).
If clinically  indicated, measurement of urin eoutput (over at least an 8-hour period ) in
patients hospitali sed ≥ 8 hours before study  drug dosing . Use of a urinary catheter is
based on the Investigator’s judgement in accordance with local standard of care.
Urinary  catheters are not required for the p urposes of this study .
Recording of results of imaging studies (e.g., chest X-ray, ultrasound, CT scan, MRI)
performed as part of the patient’s standard of care within 72 hours before the first dose
of study  drug .
Collection of blood and other specimen sfor microbiological evaluation as clinically
indicated based on the Investigator’s judgement in accordance with local standard of
care (see Section 5.4)
The Investigator will review the results of the screening assessments and procedures, 
including results of laboratory  tests, and all inclus ion/exclusion criteria to ensure patient 
eligibility .
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 38of 69
5.2.2 Active treatment visits
The following assessments and procedures will be performed during stud y treatment visits
(Day  1to Day  10 [or up to Day  14]; see Table 3):
Study  drug administration should be initiated as soon as possible after enrollment. 
Ceftobiprole medocaril will be reconstituted and diluted for IV administration and 
administered as described in the Pharmacy  Manual and in Section 6.6. If applicable, 
ampicillin and/or an aminogl ycoside will be prepared and administered according to 
the manufacturer’s instructions and/or local standard of care. The dates and exact start 
and stop times of all ceftobiprole infusions, and if applicable, of all ampicillin and/or 
aminogl ycoside infusions/injections must be recorded in the eCRF.
Physical examination : complete or brief physical examinations focusing on changes 
from baseline during t he active treatment period will be performed at the discretion of 
the Investigator as clinically  indicated in accorda nce with local standard of care
(seeSection 5.5.2)
Body weight (see Section 5.5.2) : body  weight on Day  1, which will be used for Day  1 
dose calculation, should be obtained within 12 hours prior to the first dose of study  
drug. From Day 2 until the last day of study  treatme nt, the dose should be calculated 
based on the patient’s first body  weight of the day.
Vital signs (including body  temperature, respiratory  rate, pulse rate, and systolic and 
diastolic blood pressure s) and pulse oximetry  must be recorded within 30 minutes 
before the first study  drug administration , and then three times daily  during the active
treatment period. If continuously  monitored, the highest body  temperature, respiratory  
rate, and pulse rate, and the lowest systolic and diastolic blood pressure sand oxygen 
saturation obtained during an 8 -hour period, will be recorded (see Section 5.5.3).
Signs and s ymptoms of LOS (see Section 5.6.4)
Local laboratory  tests will be performed only if clinically  indicated based on the 
Investigator’s judg ement in accordance with local standard of care ( seeSection 5.5.4).
If clinicall y indicated, measurement of urine output (over at least an 8-hour period). 
Use of a urinary  catheter is based on the Investigator’s judgement in accordance with 
local standard of care. Urinary catheters are not required for the purposes of this study.
Imaging studies (e.g., chest X-ray, ultrasound, CT scan, MRI) will be performed if 
clinically  indicated based on the Investigator’s judgement in accordance with local 
standard of care .
Collection of blood and other specimen sfor microbiological evaluation as clinically  
indicated based on the Investigator’s judgement in accordance with local standard of 
care (see Section 5.4).
Review and recording of concomitant medications, including ongoing prior 
medications, and concomitant medical procedures, including ongoing prior procedures .
Adverse events must be monitored andrecorded on an ongoing basis as outlined in 
Section 7.4.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 39of 69
PK blood sampling on Day 3: blood samples for measurement of ceftobiprole,
ceftobiprole medocaril, and open -ring metabolite concentrations will be collected
pre-dose and at 2 hours (end of infusion), 4 hours, and 8 hours, as described in detail in
the Laboratory Manual (see Section 5.4). PK samples should not be taken from the
infusion lines.
If applicable, determination of aminogly coside blood levels and monitoring for
ototoxicity  and nephrotoxicity  should be performed acc ording to the recommendations
provided in the local label and /orlocal standard of care .
5.2.3 End-of-treatment visit
The following assessments and procedures will be performed at the EOT visit ( on the day 
of last study –drug administration  or within 24hours of the last dose of study  drug; 
seeTable 3):
Physical examination (see Section 5.5.2)
Body weight (see Section 5.5.2)
Vital signs (including body  temperature, respiratory  rate, pulse rate, and systolic and
diastolic blood pressures) and pulse oximetry (see S ection 5.5.3)
Signs and s ymptoms of LOS (see Section 5.6.4)
Local laboratory  tests (see Section 5.5.4)
Collection of blood and other specimens for microbiological evaluation as clinically
indicated based on the Investigator’s judgement in accordance with local standard of
care (see Section 5.4)
Imaging tests (e.g., chest X-ray, ultrasound, CT scan, MRI) will be performed if
clinically  indicated based on the Investigator’s judgement in accordance with local
standard of care.
Overall clinical outcome assessment :clinical cure, clinical failure, or unevaluable (see
Section 5.6.1)
Microbiological outcome assessment: eradication, presumed eradication, persistence,
presumed persistence, or unevaluable (see Section 5.6.3)
Review and recording of changes in concomitant medications and concomitant
procedures
Adverse events must be monitored and recorded as outlined in Section 7.4.
5.2.4 Test-of- cure visit
The following assessments and procedures will be performed at the TOC visit (7 −14days 
after the last dose of study  drug; see Table 3):
Physical examination (see Section 5.5.2)
Body weight (see Section 5.5.2)
Vital signs (including body  temperature, respiratory  rate, pulse rate, and systolic and
diastolic blood pressures) and pulse oximetry  (see S ection 5.5.3)
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 40of 69
Signs and s ymptoms of LOS (see Section 5.6.5)
Local laboratory  tests will be performed only if clinically  indicated based on the
Investigator’s judg ement in accordance with local standard of care (seeSection 5.5.4)
Imaging tests (e.g., chest X-ray, ultrasound, CT scan, MRI) will be performed if
clinically  indicated based on the Investigator’s judgement in accordance with local
standard of care.
Collection of blood and other specimens for microbiological evaluation as clinically
indicated based on the Investigator’s judgement in accordance with local standard of
care (see Section 5.4).
Overall clinical outcome assessment: clinical cure, clinical failure, or unevaluable
(seeSection 5.6.1)
Microbiological outcome assessment: eradication, presumed eradication, persistence,
presumed persistence, or unevaluable (see Section 5.6.3)
Review and recording of changes in concomitant medications and concomitant
procedures
Adverse events must be monitored and recorded as outlined i n Section 7.4.
5.2.5 Last follow -up visit
The following assessments and procedures will be performed at the LFU visit (28−35days 
after the last dose of study  drug; see Table 3). This visit can be done by  telephone contact 
unless an examination is needed to evaluate relapse or abnormalities recorded during the 
TOC visit.
Review and recording of changes in concomitant medications and concomitant
procedures
Adverse events must be monitored and recorded as outlined Section 7.4.
Survival status
Relapse assessment : Deterioration of the clinical condition compared to the TOC
visit, microbiological recurrence ,or the requirement for additional antimicrobial
therap y forLOS
5.3 Medical history and concomitant medications
5.3.1 Medical history
A full medical history , including relevant abnormalities, surgeries, diseases, or disorders,
must be obtained at Screening.
Medical history  also includes any relevant worsening of a patient’s condition which occurs 
after consent , but prior to the start of first study -drug administration (see Section 7.2.1).
5.3.2 Prohibited c oncomitant medications
Systemic antibacterial therap y other than ampic illin and aminogl ycosides
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 41of 69
5.3.3 Permitted concomitant medications
Ampicillin and/or an aminoglycoside based on the Investigator’s judgement , local 
standard of care, and/or isolated or presumed pathogens
Topical antibacterial medications
Acetaminophen or paracetamol
Nonsteroidal anti -inflammatory  drugs and s ystemic steroids
Non-antibacterial standard -of-care medications
5.4 Microbiology assessments
Microbiological evaluation and outcome assessment may be based on blood sample s,urine , 
cerebrospinal fluid, or any other suitable specimen samples.
If clinically  indicated and performed as part of the patient’s regular medical care, blood is 
to be obtained for microbiological evaluation at the Screening visit/Baseline (if possible
before any antibiotics are administered) , orat any time through to LFU visit. Cultures 
should be repeated in accordance with standard of care if a positive result is obtained, until 
sterilization is confirmed. Gram stain, culture/PCR, and organism identification are to be 
performed at the local or regional laboratory , as applicable. All isolates, regardless of 
specimen source , are to be sent to the central microbiology  laboratory  for final organism 
identification and study -specific susceptibility  testing.
Seethe Laboratory  Manual for procedures regarding the collection, processing, storage, 
and shipment ofpathogens. Rules forthe assessment of the validity  of pathogens are 
described in the Statistical Anal ysis Plan (S AP).
5.5 Safety assessments
The Investigator will evaluate safet y by AEmonitoring, clinical laboratory  tests, vital 
signs, and phy sical examination (see schedule of a ssessments; Table 3).
Safety  assessments must be performed at intervals indicated in the schedule of assessments 
(Table 3). More frequent asses sments may  be performed at the Investigator’s discretion, if 
medically  indicated.
Safety data will be reviewed by  the S ponsor and by the DSMB (seeSection 3.4).
5.5.1 Adverse event monitoring
SeeSection 7.4for details regarding AE collection and management.
5.5.2 Physical examination
A complete physical examination will be performed at Screening and at the EOT and TOC 
visits in accordance with Table 3, and will inc lude examination of general appearance , skin, 
head, neck , eyes, ears, nose, throat, cardiovascular sy stem, thorax/ lungs, abdomen, ly mph 
nodes, extremities, and nervous s ystem.
Complete or targeted physical examinations focusing on changes from baseline will be 
performed during the active treatment period at the discretion of the Investigator as 
clinically  indicated in accordance with local standard of care.
Any clinicall y-signif icant phy sical change from baseline that occurs after first study -drug 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 42of 69
administration must be reported as an AE (see Section 7.4).
A patient’s lengt h will be measured onl y during the Screening visit.
Body weight will be measured at Screening, daily during the active treatment period, andat 
the EOT and TOC visits. The weight obtained within 12hours prior to the first dose 
ofstudy  drug will be used t o calculate the dose on Day  1. From Day  2 until the last day  of 
study  treatment, the dose should be calculated based on the patient’s first body  weight 
ofthe day .
5.5.3 Vital signs and pulse oximetry
Vital signs (including body  temperature, respiratory  rate, pulse rate, and systolic and 
diastolic blood pressures) and pulse oximetry  must be recorded during all visits from 
Screening up to and including the TOC visit (Table 3). During the active treatment period, 
vital signs must be recorded within 30 minutes before the first study  drug administration , 
and then three times daily ; if continuously  monitored, the highes t body  temperature, 
respiratory  rate, and pulse rate, and the lowest systolic and diastolic blood pressures and 
oxygen saturation obtained during an 8- hour period ,will be recorded.
5.5.4 Laboratory parameters and PK sampling
The local laboratory  tests include haematology , blood chemistry  and urine analysis 
(dipstick) parameters as per the schedule of assessments ( Table 3)and Table 4. Additional 
testing may be performed whenever clinicall y indicated at the discretion of the Investigator. 
All samples for a given study  site must be analysed by the same local laboratory  throughout 
the study, as designated by the Investigator. The results are to be pr inted, signed and dated 
by the Investigator or his/her designee.
In the event of unexplained abnormal laboratory test values, the test s must be repeated and 
followed up until return to the normal range, stabili sation, and/or until an adequate 
explanation of the abnormality  has been determined. When a clear explanation is 
established th is must be recorded in the eCRF.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 43of 69
Table 4Local laboratory parameters
Mandatory at Screening and the EOT visit; optional at active treatm ent visits and the TOC visit :
Haematology Blood chem istry Urine analysis (dipstick)
Haematocrit
Red blood cell count
White blood cell count
Absolute and immature neutrophils
PlateletsALT
AST
Bilirubin (total)
Creatinine
Sodium
Potassium
BicarbonateBlood
Glucose
Ketones
Leukocytes
Nitrite
pH
Protein
Optional at Screening and active treatm entvisits :
Blood chem istry
Anion gap
C-reactive protein
Procalcitonin
IL-6
EOT =end-of-treatment; ALT =alanine aminotransferase; AST=aspartate aminotransferase; TOC= test-of-cure.
Note : Optional blood tests maybe performed at the discretion of the Investigator in accordance with local standard of 
care, taking into consideration themaximum allowable blood draw volumes.
Seethe Laboratory  Manual for blood volumes to be drawn from each patient for the local 
laboratory  testsand for PK sampling . The combined volume of blood samples taken for 
study  purposes or as part of standard of care must not exceed the limit specified in the 
Laboratory  Manual. Any  deviation sfrom this must be clinically  justified.
5.5.5 Pregnancy testing
Not applicable .
5.6 Efficacy assessments
5.6.1 Overall clinical outcome
At the EOT and TOC visit s,the Investigator must assess the overall clinical outcome as:
Clinical cure
Signs and symptoms of LOS improved or normalised to an extent that no further
antibacterial therap y is required
Clinical failure
Discontinuation of study  treatment and requirement for non-study  antibacterial
therap y because of:
oInsufficient therapeutic effect associated with study  treatment, including
persistence or worsening of signs and s ymptoms of LOS
oAE related to the stud y treatment
Death attributable to LOS
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 44of 69
Unevaluable
Study  data not available for evalua tion of efficacy  for an y reason, including:
oLost to follow -up
oReceived < 48hours of study  treatment
oConcomitant treatment with a systemic antibacterial administered for a reason 
other than LOS, which is active against the isolated LOS pathogen, or in the 
absence of microbiological evaluation, is active against common LOS 
pathogens
oDiagnosis of any of the following conditions after enrollment in the study  and 
discontinuation of study  treatment: ventilator -associated pneumonia, 
meningitis, brain absce ss, osteomy elitis, infective endocarditis, or necrotising 
enterocolitis
oDeath in which LOS is clearl y non-contributory
oAbsence of clinical assessment for an y reason
5.6.2 All- cause mortality
Vital status will be assessed at the LFU visit, whether performed in person or b y telephone 
contact.
5.6.3 Microbiological outcome
The microbiological outcome categories at EOT and TOC are defined below . For a patient 
to have a favorable microbiological response, the outcome for each baseline pathogen must 
be eradicated or presum ed eradicated. If the outcome for any pathogen is persistence or 
presumed persistence, the patient will be considered to have an unfavorable
microbiological response.
Microbiological outcome is tobe assessed at the EOT and TOC visits by the Investigator
as follows
Eradication : Absence of baseline pathogen in follow -up cultures of source specimen
Presumed eradication : Absence of follow -up microbiological evaluation of source 
specimen, or unavailable microbiological results ,fora patient with a valid baseline 
pathoge n who was assessed as a clinical cure
Persistence : Continued presence of a baseline pathogen in follow -up cultures of any 
source specimen
Presumed persistence : Absence of follow -up microbiological evaluation of source 
specimen or unavaila ble microbiological results fora patient with a valid baseline 
pathoge nand assessed as a clinical failure
Unevaluable : No valid pathogen identified at baseline, or no follow -up microbiological 
evaluation of source specimen obtained in a patient with clinical outcome assessed as 
unevaluable
Relapse : Baseline pathogen detected again in follow -up microbiological evaluation of 
any source specimen obtained between the TOC and LFU visits after documented 
eradication or presumed eradication at the TOC visit (note: this applies only to the 
microbiological outcome assessment at the LFU visit)
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 45of 69
5.6.4 Relapse at LFU
At the LFU visit,the Investigator must assess relapse as follows:
Deterioration of the patient’s clinical condition compared to the TOC visit,
microbiologic alrecurrence ,or the requirement for additional antimicrobial therap y for 
LOS
5.6.5 Signs and symptoms of LOS
The Investigator must rate the following signs and sy mptoms of LOS as :
‘absent ’or ‘present’ at baseline (pre -dose) 
‘absent ’, ‘improved’ , ‘unchanged’ or ‘worsened’ compared to baseline ,on every  day 
of active stud y treatment, and at the EOT , TOC , and LFU visits
1.Fever (> 38.0 °C/ 100.4 °F rectal; > 37.5 °C/ 99.5 °F axillary ; >37.5 °C/ 99.5 °F 
oral; > 38.0 °C/ 100.4 °F ty mpanic)
2.Hypothermia (< 36.6 °C/ 97.9 °F rectal; < 36.5 °C/ 97.7 °F axillary ; 
< 35.5 °C/ 95.9 °F oral; < 35.8 °C/ 96.4 °F ty mpanic)
3.Abnormal heart rate
a.Brad ycardia (<100 beats/minute awake; < 80 beats/minute asleep)
b.Tach ycardia (> 205 beats/minute awake; > 160 beats/minute asleep )
4.Signs of impaired circulation
a.Urine output 0.5 –1mL/kg/h (in patients with urinary  catheters; note: urinary  
catheters are not required for the purposes of this study )
b.Hypotension
c.Signs of impaired peripheral perfusion, such as mottled skin, moist and cold skin, 
finger to forearm temperature gradient, or increased capillary  refill time
5.Petechial rash OR sclerema neonatorum
6.Respiratory  distress
a.New onset or worsening of apnea episodes
b. T achypnea episodes
c.Increased oxy gen requirements
d. R equirement for ventilatory  support ( note: proven ventilator -associated 
pneumonia is an exclusion criterion; see Section 4.3)
7.Gastrointestinal distress
a.Feeding intolerance
b. P oor sucking
c.Abdominal distension
8.Irritability
9.Lethargy
10.Muscular hypotonia
5.7 Pharmacokinetic assessments
PK will be assessed by  means of sparse blood sampling on Day  3: pre -dose and at 2 hours 
(end of infusion), 4 hours, and 8 hours, as described in detail in the Laboratory Manual.
PK samples should not be taken from the infusion lines.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 46of 69
6STUDY TREATMENT
6.1 Blinding
This is an open- label study .
6.2 Randomi zation
This is a single -arm study. At least two term (gestational age ≥37 weeks) and sixpre-term 
(gestational age ≥ 24 to 36 weeks) neonates and infants , with post- natal age ranging from 
≥3 day s to ≤3 months will be enrolled , with no stratification.
6.3 Packaging and label ling
The study  drug will be packed and label ledin accordance with local regulations and the 
Annex 13 Good Manufacturing Practice rules . Labels will include t he identity  of the 
Sponsor and Investigator, protocol number, drug identification, storage conditions, content 
of study  drug, and expiry date. Information on drug shipment including temperature logger 
and acknowledg ement of receipt form to be completed by the receiver will also be included.
6.4 Shipping and storage conditions
Vials of sterile lyophili sed ceftobiprole medocaril containing the equivalent of 500mg 
ceftobiprole will be shipped to the study  sites, and the dry powder must be stored in a 
refrigerator (2−8°C / 36−46 °F). All study  drug must be kept under secure conditions, 
e.g., in the hospital pharmacy .
Further information on the shipping and storage conditions is provided in the 
Pharmacy Manual.
6.5 Preparation , presentation, and stability of study drug
Details on the presentation, preparation (including reconstitution and dilution steps), and 
stability  of study  drug are provided in the Pharmacy  Manual.
6.6 Dosage and administration of study drug
Eligible patients will receive ceftobiprole as a 2-hour IV infusion according to the schedul e 
inTable 5, with dose adjusted according to gestational and post-natal ages. Body weight 
on Day 1 should be obtained within 12 hours prior to the first dose of study  drug. From 
Day 2 until the last day of study  treatment, the dose should be calculated based on the 
patient’s first body  weight of the day .
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 47of 69
Table 5Ceftobiprole dosing regimen for the treatment of neonates and
infants with LOS
Gestational age 
group (weeks)Post-natal age (days)
3 –13 14 –29 30 –59 60 –90
24 –26 7.5mg/kg q12h 7.5mg/kg q12h 10 mg/kg q12h 10 mg/kg q12h
27 –31 10mg/kg q12h 10 mg/kg q12h 10 mg/kg q12h 15 mg/kg q12h*
32 –36 10mg/kg q12h 10 mg/kg q12h 15 mg/kg q12h*15mg/kg q12h*
≥37 15mg/kg q12h*15mg/kg q12h*15mg/kg q12h*15mg/kg q8h*
Note : All doses will be infused over 2 hours. The maximum allowable dose in adult and pediatric patients is 500 mg 
regardless of body weight.
*Neonates and infants with a body weight < 4kg should receive a maximum of 10 mg/kg/dose.
If ampicillin and/or an aminogly coside are added, these IV solutions must not be mixed 
with ceftobiprole or administered through the same line as ceftobiprole. For further details, 
seethe Pharmacy  Manual.
6.7 Compliance and drug -supply accountability
The Investigator, and a pharmacist or a pharmacist delegate assigned by the Investigator, 
must maintain records of the deliv ery of stud y drug to the site, the inventory at the site, the 
use by each patient, and the return to the Sponsor or alternative disposal of unused product.
A Drug Dispensing L og must be kept current and must contain the following information:
Identificatio n of the patient to whom the drug was dispensed
Principal I nvestigator name
Dates, quantity  and batch number of the drug dispensed to the patient
Quantity  of the drug remaining
The inventory  must be available for inspection by the Sponsor’s monitor(s). All supplies, 
including partially  used or empty  vials, must be available for checking by the Sponsor’s 
monitor(s) during monitoring visit sand at the end of the study .
6.7.1 Drug disposal
Any remaining drug, including empty  vials, may be returned to the study  supply  packaging 
provider, or may be destroy ed at the site ontherequest of the Sponsor provided the drug 
destruction is adequatel y documented. 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 48of 69
7 SAFETY
The role of the DSMB in ensuring the protection of patient s’safet y is described in 
Section 3.4. 
Stopping criteria for individual patient s are described in Section 4.4.
7.1 Warnings and precautions
7.1.1 Ceftobiprole
Detailed warnings and precautions related to ceftobiprole are provided in the IB.
Serious and occasionally fatal adverse reactions have been reported in patients receiving 
beta-lactam antibiotics, including hypersensitivity  ( anaphy laxis) and
Clostridioides difficile -associated colitis or pseudomembranous colitis. Seizures have been 
associated with the use of ceftobiprole, most commonly  occurring in patients with 
pre-existing central nervous system/seizure disorders. Precipitation can occur when 
ceftobiprole medocaril is mixed with calcium -containing solutions in the same IV 
administration line. Therefore, ceftobiprole medocaril and calcium -containing solutions, 
except Lactated Ringer’s solution for injection, must not be mixed or administered 
simultaneously  in the same intravenous line.
7.1.2 Ampicillin / aminoglycosides
The safety  profiles of these standard -of-care antibiotics that may be combined with 
ceftobiprole at the discretion of the Investigator are well characteri sed due to their use over 
many years, and are described in their respective local labels.
Serious or significant adverse reactions that may occur in patients receiving ampicillin 
include hypersensitivity (anaph ylaxis) and Clostridioides difficile -associated colitis or 
pseudomembranous colitis. Concurrent administration of ampicillin and allopurinol 
increases substantially  the incidence of skin rashes.
Aminogl ycosides generally  have a narrow therapeutic window and therapeutic drug 
monitoring should be considered in patients treated with aminogl ycosides to ensure 
adequate therapeutic exposure and to avoid toxicity  due to overexposure. Relevant adverse 
reactions include among others hypersensitivity , ototoxicity , nephrotoxicity , impaired 
neuromuscular transmission, convulsions, and Clostri dioides difficile -associated colitis or 
pseudomembranous colitis.
If ampicillin and/or an aminogly coside are added, these IV solutions must not be mixed 
with ceftobiprole or administered through the same line as ceftobiprole.
7.1.3 Contraception and pregnancy
Not applicable.
7.2 Definitions
7.2.1 Adverse event
An AE is defined as any untoward medical occurrence in a patient or clinical 
investigational patient administered a pharmaceutical product that does not necessaril y 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 49of 69
have a causal relationship with study -drug treatment. An AE can therefore be any 
unfavo urable and unintended sign (for example, including an abnormal laboratory  finding), 
symptom, or disease temporally associated with the use of a medicinal product, whether or 
not considered related to the medicina l product. Complications associated with scheduled 
procedures are considered AEs.
Events that occur following the full execution of the I CF but prior to dosing are discussed 
inSection 7.4.2.
Adverse events will be coded using the standard Medical Dictionary for Regulatory 
Activities (MedDRA), and grouped b y System Organ Class and Preferred Term.
7.2.2 Serious adverse event
An SAE is a ny AE that meets 1 or more of the following criteria:
Results in death
Is life -threatening
Requires inpatient hospitalisation, or prolongation of existing hospitalis ation
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is classified as an important medical event or medically  significant event
Medical and scientific judgement should be exercised in deciding whether an AE should 
be considered an important medical event (and consequently  an SAE). Such events may 
not be immediately  life-threatening or result in death or hospitali sation, but may jeopardi se 
the patient, or may require intervention to prevent one of the outcomes listed in the 
definitions above. These situations should also usually  be considered serious.
It should be noted that:
Death is considered an outcome of an AE. Whenever possible the underly ing cause of 
death must be reported as the AE.
A life- threatening SAE is any  adverse experience that places the patient at risk of death 
at the time of its occurrence, i.e., it does not include a reaction that, had it occurred in 
a more severe form, might have caused death.
Inpatient hospitali sation is defined as any inpatient admission, even if for less than 
24hours. For chronic or long-term inpatients, inpat ient admission also includes transfer 
within the hospital to an acute/intensive care inpatient unit.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 50of 69
The following hospitalis ations, whether planned before or during the study , should not be 
considered and reported as SAEs:
Routine treatment not associated with an y deterioration in condition
Elective or planned treatment, including surgical interventions, both related and
unrelated to the patient’s LOS, if the plan for the respective intervention was
documented prior to the first dose of study  drug
Elective or pre-planned treatment for a pre-existing condition that is unrelated to the
patient’s LOS and has not worsened
Admission to a hospital or other institution for general care, not associated with any
deterioration in condition
7.2.3 Adverse drug reac tion
In the context of this study protocol, an ADR or serious adverse reaction (SAR) isan AEor 
SAE respectively  for which there is a reasonable possibility  that the drug caused the 
event, i.e.,it has been assessed by the Investigator and/or the Sponsor as either 
Possibly related or Probably related to the study  drug or to ampicillin or an 
aminogl ycoside (seeSection 7.3.2).
7.2.4 Suspected unexpected serious adverse reaction
A suspected unexpected serious adverse reaction (SUSAR) is any  SAE considered by  the 
Investigator or b y the Sponsor to be Possibly related or Probably related to the study  drug
or to ampicillin or an aminogly coside (see Section 7.3.2), which is not listed in the 
Reference Safet y Information applicable at the time of occurrence of the event ,or is not 
listed at the specificit y (i.e., nature, outcome) or severity  that has been observed.
7.2.5 Adverse events of special interest
An adverse event of special interest (AESI) is defined as a serious or non -serious AE th at 
is of scientific and medical concern specific to the sponsor’s product for which ongoing 
monitoring and rapid communication by the investigator to the sponsor can be appropriate.
The following are considered AEs of special interest for the purposes of this study , based 
on nonclinical data and the known safety  profile of ceftobiprole or the cephalosporin class 
of antibiotics. and are to be promptl y reported in the eCRF, along with an assessment of 
relationship by  the Investigator :
Hypersensitivity  reactio ns
Convulsions
Clostridioides difficile -associated colitis or pseudomembranous colitis
Hepatic enz yme increased
Hyponatremia
Renal failure
Infusion site reactions
Thromboembolic events
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 51of 69
7.2.6 Further adverse event definitions
Wherever possible, a specific disease or syndrome rather than individual associated signs 
and s ymptoms should be identified. However, if an observed or reported sign or s ymptom 
is not considered by  the Investigator to be a component of a specific disease or sy ndrome, 
it should be recorded as a separate AE.
Laboratory  data are to be collected as stipulated in Section 5.5.4. Clinical syndromes 
associated with laboratory  abnormalities are to be recorded as appropriate (e.g., diabetes 
mellitus instead of hy pergl ycemia).
7.2.7 Special Situations
Special Situations include overdose, misuse, and medication error. A Special Situation may 
occur with or without an associated AE.
Overdose: Administration of a quantity  of a medicinal product once or cumulatively
which is above the maximum recommended dose indicated in the author ized product
information or administration specification set out in this protocol. Clinical judgement
should alway s be applied when appl ying this definition.
Misuse of a medicinal product: Intentional and inappropriate use of a medicinal
product not in accordance with the terms indicated in the authorized product
information or administration specification set out in this protocol .
Medication error: An unintended failure in the drug treatment process that leads to, or
has the potential to lead to, harm to the patient.
7.3 Evaluation of adverse events
7.3.1 Grading of severity
The severit y of an AE will be graded on the following scale:
Mild : no change in basel ine age appropriate behaviour*
Moderate : resulting in minor changes of baseline age-appropriate behaviour
Severe : resulting in major changes of baseline age-appropriate behaviour*and/or
non-life threatening changes in basal ph ysiological processes**
Life-threatening
Fatal
*Age-appropriate behaviour refers to oral feeding behaviour, voluntary movements and activity, crying
pattern, social interactions and perception of pain
**Basal physiological processes refer to oxygenation, ventilation, tissue perfusion, metabolic stability and 
organ functioning
7.3.2 Assessment of causality
The relationship between an AE and the study  drug will be determined b y the Investigator 
on the basis of th eir clinical judg ement and the following definitions.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 52of 69
To align with the binary causality assessment required for clinical studies, based on the 
Investigator’s evaluations, the cases will be categori sed as:
Unrelated : when evaluated as Unlikely related or Not related to the study  drug or to 
ampicillin or an aminogly coside
Related: when evaluated as Probably related or Possibly related to the study drug or to 
ampicillin or an aminogly coside
UNRELATED
This category  comprises events that are either
Not related to the study  drug or to ampicillin or an aminogl ycoside , i.e., clearl y and 
incontrovertibly  due only to extraneous causes such as the patient’s clinical state, 
environmental or toxic factors, or other modes of therapy  administered to the patient, 
or
Unlik ely related to the study drug or to ampicillin or an aminogl ycoside , i.e., the event 
may readily  have been produced by  the patient’s clinical state, environmental or toxic 
factors, or other modes of ther apy administered to the patient
An AE is also categori sed as Unlikely related / Not related if it does not follow a reasonable 
temporal sequence from administration of the study  drug or ampicillin and/or an 
aminogl ycoside , i.e.,based on the time between the administration of study  drug and 
occurrence of the event, a relationship is not plausible.
Examples for the absence of a reasonable temporal sequence from administration of the 
study  drug are that the drug was:
Re-administered, and the event did not recur, or
Interrupted or stopped, and the eve nt did not improve or disappear
Finally , an AE may  be assessed to be Not related / Unlikely related if it does not follow a 
known pattern of the response to the study  drug or drugs of the same substance class.
RELATED
Probably related
This category  is applicable to an AE thatis considered, with a high degree of certainty , to 
be related to the study  drugor to ampicillin and/or an aminogl ycoside (i.e., this categor y 
also comprises events that are definit ely related to the study  drug).
An AE event may beconsidered (at least) Probably related (or considered definitel y 
related) to the study  drugor ampicillin and/or an aminogl ycoside if it meets oneor more 
of the following criteria:
It follows a reasonable temporal sequence from administration of the study drug or 
ampicillin and/or an aminogl ycoside , i.e.,based on the time between the administration 
of study  drug and the occurrence of the event, a r elationship is plausible, e.g.,
–The drug was interrupted or stopped, and the event improved or disappeared
–The drug was re -administered, and the event recurred
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 53of 69
It follows a known pattern of the response to the suspected drug or drugs of the same 
substance class
It cannot be reasonably  explained by  the known characteristics of the patient’s clinical 
state, environmental or toxic factors, or other modes of therapy administered to the 
patient
Possibly related
An AE may be considered to be (at least) Possibly related to the study  drug or treatment 
with ampicillin and/or an aminogl ycoside if:
It follows a reason able temporal sequence from administration of the study  drugor 
ampicillin and/or an aminogl ycoside (seealso additional explanations above), or it 
follows a known pattern of the response to the suspected drug or drugs of the same 
substance class; or
It ma y or may  not have been produced by  the patient’s clinical state, environmental or 
toxic factors, or other modes of therap y administered to the patient; or
It does not follow a plausible temporal relationship or a known pattern of response but 
there is no a lternative explanation for the event.
7.4 Handling of safety information and collection periods
7.4.1 Responsibilities and procedures
The responsibility  for the safet y of an individual patient lies in all cases with the 
Investigator . This includes the timely  review of all safety  data obtained during the course 
of the study .
An Investigator must instruct the parent(s) or LAR to report any AEs the patient 
experience s.
7.4.2 Handling of safety d ata during the pre -treatment period
Any relevant change in, or worsening of, a patient’s condition occurring after execution of 
the study  ICF but prior to dosing, is to be recorded in the medical history  page of the eCRF 
(see Section 5.3.1), unless the occurrence is assessed as related to the study procedure, in 
which case it must be recorded in the AE page. If the event is assessed as both serious (see 
Section 7.2.2) and related to study -specific procedures , itmust be reported to the Sponsor’s 
safet y representative, using the same procedures as for an SAE (see Section 7.4.3.2).
7.4.3 Handling of safety d ata during the treatment period and up to the last 
scheduled follow -up
From the start of first dosing up toand including the LFU visit 28−35 days after the last 
study  drug administration, any change in, or worsening of, a patient’s condition, all AEs, 
and Special Situations must be collected and reported in the eCRF (See Section 9.1.2).
SAEs must in addition be reported and recorded on the SAE form (see Section 7.4.3.2).
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 54of 69
7.4.3.1 Reporting procedures for adverse events that do not meet seriousness 
criteria
All AEs directl y observed (physical examination, laboratory  test, or other assessments), 
mentioned by the parent(s) or LAR , or reported by the parent(s) or LAR upon non-directive 
questioning, must be recorded on the AE pages of the eCRF in the English language, and 
should include the following information:
The term identify ing the event. If possible, a diagnosis should be documented rather 
than signs and symptom s, using self-explanatory  and concise medical terminology . If 
an observed or reported sign or symptom is not considered a component of a speci fic 
disease or syndrome by the Investigator, it should be recorded as a separate AE. 
Note that disease progression is considered an efficacy outcome parameter, and should 
not be recorded as an AE unless the outcome is death.
Duration (start and end dates)
Grading of severit y (see Section 7.2.3)
Relationship to study  drug (causalit y assessment) (see Section 7.3.2)
Action taken in regard to study drug or ampicillin and/or an aminogly coside or any 
suspected concomitant medication
Additional treatments given for the event
Whether the event is an SAE (seriousness assessment) (see Section 7.2.2)
Outcome
Further details on completing the relevant pages in the eCRF are provided in the eCRF 
completion guidelines. In addition, concomitant medications (with start and stop dates) and 
medi cal history  should be updated as needed.
Abnormal laboratory  results should not be recorded as an AE unless the abnormal result
meets 1 or more of the following criteria:
Induces clinical signs or symptoms which require therapy  or additional diagnostic 
evaluation
Requires study  drug dose modification or discontinuation
Is considered clinicall y significant
If a laboratory  abnormality  meets 1of the above criteria, the clinical sy ndrome associated 
with the laboratory  abnormality  is to be recorded (e.g., diabe tes mellitus instead of 
hypergly cemia).
Adverse events must also be reported in the source document with at least the nature of the 
event, the start and end date, the relationship to study  drug, treatment (ifapplicable), and 
outcome (in the initial or fol low-up report).
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 55of 69
7.4.3.2 Reporting procedures for serious adverse events
7.4.3.2.1 Investigator’s responsibility
In addition to being reported and followed up as AEs (see Section 7.4), events which are 
classified as SAEs, must be reported to the Sponsor’s safet y representative listed below, 
within 24 hours of awareness of the event.
In addition to completion of the SAE form, such reports may include detailed anonymis ed 
descriptions (e.g., discharge letter, autops y report) and/or relevant data (e.g., ECG, 
laboratory  tests, discharge summaries, post-mortem results). If any questions arise, the 
Sponsor’s m edical m onitor or designee should be consulted.
The information provided in an SAE form should be as complete as possible, but must at a 
minimum include the following:
The diagnosis / short description of the AE, and the reason for categori sing the AE as
serious
Patient ID and treatment (if applicable)
Investigator’s name and phone number (if applicable)
Name of the suspect study  drugor ampicillin or an aminogl ycoside and dates of
administration
Assessment of causality
If all information about the event is not yet known, the Investigator will be required to 
report any additional information within 24 hour s, and further information as it becomes 
available.
The Investigator or designee must notify  the applicable IEC/I RB of the event in line with 
local requirements.
7.4.3.2.2 Sponsor’s responsibilities
The Sponsor must ensure the reporting of SUSARs and any expeditable SAEs to Health 
Authorities and IECs/I RBs in accordance with applicable laws and regulations.
In the event of a SUSAR , the Sponsor must ensure that Investigators active in any other 
interventional studies with the study  drug for which it is the Sponsor are informed.
[STUDY_ID_REMOVED]

 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 56of 69
Expectedness of SAEs for regulatory  expedited reporting will be assessed by the Sponsor 
against the applicable Reference Safet y Information of the study  drug; for ceftobiprole , the 
Reference Safet y Information is found in the I Bin effect at the time of onset of the event.
7.4.4 Follow -up of adverse events
Once an AE is detected, it must be proactivel y followed at each visit (or more frequently  
if necessary ) for any changes in severit y, relationship to the study  drug, interventions 
required for treatment, and the event’s outcome.
All AEs must be followed up until they have returned to baseline status or resolved to 
Grade 1, have stabili sed, or until the scheduled LFU visit.
Unresolved ADRs, SARs, and unrelated SAEs at the time of the LFU visit must be 
followed up until they have, in the opinion of the Investigat or, resolved to baseline, 
Grade 1, stabili sed, or are deemed to be irreversible (including death), or until the parent(s) 
or LAR withdraw their consent.
7.4.5 Handling of post -study safety data
After the LFU visit, only SARs should be collected and reported; however, these events 
are not captured in the eCRF.
New SARs that occur after the LFU visit will be followed until they have, in the opinion 
of the Investigator, resolved to baseline, stabilised, or are deemed to be irreversible 
(including death), or until the parent(s) or LAR withdraw their consent for participation of 
the patient in the study .
7.4.6 Reporting and handling of pregnancies
Not applicable.
7.5 Adverse events associated with an overdose or any other Special 
Situation
Any overdose or any other Special Situation (with or without an AE) should be recorded 
in the eCRF.
All AEs associated with an overdose or medication error should be recorded on the eCRF 
(see Section 9.1.2). If the associated AE is assessed as an SAE, the event should be reported 
to the Sponsor immediately  (see Section 7.4.3.2).
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 57of 69
8 STATISTICAL CONSIDERATIONS AND ANALY TICAL PLAN
Details of the statistical analyses presented below will be provided in the SAP. A change 
to the data analy sis methods described in the protocol will require a protocol amendment 
only if it alters a principal feature of the protocol. The SAP will be finalis ed prior to 
database lock. Any changes to the methods described in the plan will be described and 
justified in the final clinical study  report.
8.1 Study endpoints
8.1.1 Primary endpoint
The primary  endpoint is safet y and tolerability in the Safety  population , as assessed by 
AEs, SAEs, deaths, and discontinuations due to AEs during treatment with ceftobiprole 
and at the EOT, TOC, and LFU visits, as well as clinical laboratory  tests, vital signs, and 
physical examination findings.
8.1.2 Secondary endpoints
Pharmacokinetics
Plasma levels of ceftobiprole, ceftobiprole medocaril ,and open -ring metabolite in the 
PK population
Efficacy
Clinical cure rate at the EOT and TOC visits (ITT and CE populations)
All-cause mortalit y through Day  28(ITT population)
Microbiological eradication or presumed eradication rate at the EOT and TOC visits
(mITT and ME populations)
Improved signs and s ymptoms of LOS at the Day 3, EOT, and TOC visits (ITT and CE 
populations)
8.2 Analysis populations
The following anal ysis populations are defined for this study :
8.2.1 Intent -to-treat (ITT) population / Safety population
All patients enrolled in the study who received at least onedose of ceftobiprole .
8.2.2 Clinically Evaluable (CE) population
Patients in the ITT population who received at least 48 hours of study  treatment
(i.e., four or sixinfusions of ceftobiprole as applicable) and had a completed overall 
clinical outcome assessment at the TOC visit, no major protocol deviations, and no 
concomitant sy stemic non -study  antibiotic therapy .
8.2.3 Microbiological I ntent -to-treat (mITT) population
All patients in the I TT population with a valid pathogen identified at baseline.
8.2.4 Microbiologically Evaluable (ME) populat ion
All patients in the CE analy sis population with a valid pathogen identified at baseline and 
a microbiological outcome assessment at the TOC visit.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 58of 69
8.2.5 Pharmacokinetic s(PK) population
All patients who received ceftobiprole and had at least onesample of plasma concentration 
measurement obtained by  the appropriate methodology .
8.3 Sample size considerations
The study  is not powered for inferential statistical analy sis. The sample size (eight patients; 
twoterm and sixpre-term) is considered adequate to evaluate the safet y of ceftobiprole in 
neonates and young infants with L OS.
8.4 Statistical and analytical methods
There will be no formal hypothesis testing in this study . Descriptive statistics will be 
applied to the primary  and secondary  endpoints as follows: number, mean, standard 
deviation, median, minimum, and maximum will be provided for continuous variables, and 
frequency  distributions (counts and percentages) will be shown for categorical variables. 
All variables will be summari sed overall and by gestational and post-natal ages as 
appropriate. Variables may be compared to baseline where applicable. Listings of 
individual patients’ data will also be produced.
A full Statistical Analy sis Plan will be prepared before database lock.
8.4.1 Primary endp oint analysis
8.4.1.1 Safety/tolerability analysis
Safety  will be assessed through summaries of AEs, clinical laboratory  tests, vital signs, and 
physical examination findings. All safety anal yses will be based on the Safety  population.
The incidence of AEs and SAEs will be tabulated by System Organ Class (SOC) and 
Preferred Term (PT), and by severit y, relationship to treatment, and outcome. Tables of 
AEs leading to study  drug discontinuation and withdrawal from the study  will also be 
provided.
Adverse occurrence s (as defined in Section 7.2) will be provided in a listing.
Descriptive statistics summarising local laboratory  data will be presented by study visit. 
The change fr om baseline to each post -baseline visit and to the overall worst post -baseline 
value will also be summarised.
Descriptive statistics of vital signs will be presented by study visit, as well as the change 
from baseline at each study  visit. The percentage of abnormalities in the physical 
examination will be presented b y study  visit.
8.4.2 Secondary endpoint analyses
8.4.2.1 Pharmacokinetic analysis
Descriptive summary  statistics of plasma concentrations of ceftobiprole , ceftobiprole 
medocaril, and open -ring metabolite in the PK population will be presented by timepoint 
and by gestational and post-natal ages.Population PK model ling, Monte Carlo simulations, 
and PK- PD anal yses will be reported separatel y.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 59of 69
8.4.2.2 Efficacy analyses
The following efficacy  assessments will be analy sed using descriptive statistics:
Clinical and microbiological outcome assessments at the EOT and TOC visits
(clinical outcomes in the ITT and CE populations; microbiological outcomes in the 
mITT and ME populations)
All-cause mortalit y through Day  28(ITT population)
Signs and symptoms of LOS at the Day 3, EOT and TOC visits (ITT and CE 
populations)
8.4.3 Study drug exposure and compliance
The actual dose, duration in days,and compliance of the study drug will be listed by patient 
and summari sed through descriptive statistics in the safet y population.
8.4.4 Prior and c oncomitant treatments
Medications and significant non-drug therapies used prior to and after the start of the study  
drug will be listed by patient and summarised by Anatomical Therapeutic Chemical term 
and Preferred Term .
8.4.5 Handling of missing data and discontinuations
Missing data will not be imputed. Patients whose clinical response is unknown or not 
repor ted will be treated as non -responders.
Reasons for discontinuation and the date of discontinuation will be listed.
9 STUDY ADMINISTRATION AND REGULATORY ASPECT S
9.1 Study records
The Investigator must maintain adequate and accurate records to enable the conduct of the 
study  to be full y documented and the study  data to be subsequentl y verified.
9.1.1 Investigator SiteFile
The ISFmust contain all essential documents as required by Internation al Council for 
Harmoni sation (ICH) E6 and applicable regulations, including the IB, this protocol and 
any subsequent amendments, eCRFs, Query  Forms, documented IEC/IRB approvals, 
documented regulatory  approvals, sample ICFs, drug records, staff curriculum vitae, and 
other appropriate documents/correspondence.
9.1.2 Case report forms
For each patient enrolled in the study , including patients who do not complete the study  
and patients for whom an eCRF is initiated during Screening but who are not dosed, an 
eCRF must be completed and signed by the Investigator or authori sed site staff. If a patient 
discontinues from the study , the reason must be noted on the eCRF. If a patient is 
discontinued from the study  because of an AE, thorough efforts should be made to clearl y
document the outcome.
The Investigator should ensure the accuracy , completeness, legibility , and timeliness of the 
data reported to the Sponsor in the eCRFs and in all required reports.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 60of 69
If the eCRF is to be the source document for certain data, this must be discussed and agreed 
with the Sponsor in a dvance, and clearl y documented.
9.1.3 Patient source documents
Patient source documents used to record key efficacy /safet y parameters, independent of 
the eCRFs, may  include, but are not limited to, patient hospital/clinic records, phy sicians’ 
and nurses’ notes, appointment books, original laboratory  reports, X-ray, pathology  and 
special assessment reports, signed ICFs, consultant letters, and patient screening and 
enrollment logs. Source documents are part of the study documents, and must be 
maintained and made available upon request for clinical monitoring visits, audits or 
inspections.
9.1.4 Document retention and archiving
The Investigator must keep all study  documents on file for at least 25 years after completion 
or discontinuation of the study , unless otherwise required by applicable laws or regulations. 
Subsequentl y, the Sponsor will inform the Investigator when the study  documents can be 
destroy ed, subject to applicable regulations.
These files must be made available for audits and inspection, upon reasonable request, 
tothe authori sed representative of the Sponsor, or to Health Authorities.
Should the Investigator wish to assign the stud y records to another party , or move them to 
another location, the Sponsor must be notified in advance.
If the Investigator cannot guarantee the archiving requirement at the study  site for any or 
all of the study  documents, arrange ments must be made between the Investigator and the 
Sponsor for appropriate storage.
9.2 Clinical m onitoring
Before study  initiation, at a site initiation visit, the Sponsor will review the protocol, eCRFs 
and othe r stud y documentation with the Investigators and the site staff.
The monitor must visit the Investigator and the study  facilities on a regular basis throughout 
the study  to verify  adherence to GCP and this protocol, and the completeness, consistency 
and accuracy  of the data being entered in the eCRFs. The monitor must also ensure that the 
study  drug is being stored, dispensed, and accounted for in accord ance with specifications.
The Investigator must ensure that the monitor has direct access to all required study  data 
(source documents) during the regular monitoring visits. This includes all patient records 
needed to verify  the entries in the eCRFs.
The Investigator must cooperate with the monitor to ensure that any protocol deviations or 
other issues detected in the course of monitoring visits are resolved.
Monitoring reports must be written after each monitoring visit, per site and per visit. These 
monit oring reports must be reviewed and approved by the respective supervisors of the 
Monitors.
Further monitoring instructions are provided in the Monitoring Plan.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 61of 69
9.3 Audits and inspections
The study  may be audited at any time, with appropriate notification, by qualified personnel 
from the Sponsor or its designees, to assess compliance with the protocol, GCP, and 
regulatory  requirements. These audits may also be conducted for quality  assurance 
purposes to ensure that complete and accurate data are submitted, and that all AEs are being 
identified and reported in compliance with the protocol and applicable regulations. The 
study  may  also be audited by  Health Authority  inspectors, after appropriate notification. 
In the event of an audit or an inspection, the Investig ator must ensure that direct access to 
all study  documentation, including source documents, is granted to the auditors or 
inspectors.
9.4 Protocol a mendments
Protocol amendments must be prepared by a representative of the Sponsor, andbe reviewed 
and approved in accordance with the Sponsor’s Standard Operating Procedure s(SOPs) .
All protocol amendments must be submitted to the appropriate IEC/I RB for information 
and approval, in accordance with applicable laws and regulations, and to Health Authorities 
if required.
Approval of a protocol amendment must be awaited before changes are implemented, 
with the exception of changes that are necessary to eliminate an immediate hazard to 
study participants, or changes involving only logistical oradministrative aspects of the 
study  (e.g., changes to monitors, changes to telephone numbers).
9.5 Premature termination of the study
The Sponsor reserves the right to terminate the study  at any time (see Section 4.6). 
AnInvestigator has the right to terminate his or her participation in the study  at any time. 
Should either of these events occur, both parties will arrange the necessary  procedures after 
review and consult ation.
If the study  is to be termina ted early, the Sponsor and the Investigator must ensure that 
adequate consideration is given to the protection of the interests of all patients enrolled in 
the study .
9.6 Publication policy
The Sponsor is committed to registering this study  in a publicl y accessible clinical trial 
registry  (e.g., www.clinicaltrials.gov ), and will ensure that the results of this study  will be 
made available to the medical community  consistent with the ICH GCP guidelines, the 
Sponsor’s SOPs, applicable laws and regulations, and the Good Publicat ion Practice 
(GPP3) guidelines.
The Sponsor will prepare a clinical study  report for submission to Health Authorities 
providi ng the results of all planned anal yses within 6months after t he end of the study .
This study  is intended for publication, even if terminated prematurel y. Publication may 
include an y or all of the following: posting of a s ynopsis online, submission of an a bstract 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 62of 69
and/or presentation at a scientific conference, or publication of a full manuscript. 
TheSponsor will work with the authors to submit a manuscript describing study  results.
These timelines may be extended if additional time is needed for analysis, to protect 
intellectual propert y, or to comply  with confidentiality  agreements with other parties. 
Authors of the primary  results manuscript will be provided the complete results from the 
clinical study  report, subject to applicable confidentiality  agreeme nts.
When a manuscript is submitted to a biomedical journal, the Sponsor’s policy  is to also 
include the protocol and SAP to facilitate peer and editorial review of the manuscript. Ifthe 
manuscript is subsequently  accepted for publication, the Sponsor will allow the journal to 
post on its website the key sections of the protocol that are relevant to evaluating the study , 
specificall y including those sections describing the study  objectives and hypotheses, the 
inclusion and exclusion criteria, the study  design and procedures, the efficacy  and safet y 
measures, the SAP, and any relevant protocol amendments. The Sponsor reserves the right 
to redact proprietary  information from these documents.
As this is a multicenter study , subsequent to the multicenter publication (or after public 
disclosure of the results online at www.clinicaltrials.gov if a multicenter manuscript is not 
planned), an Investigator and his or her colleagues may publish their data independentl y. 
The limitations of single study  site observations in a multicenter study  should alway s be 
described in such a manuscript.
Authorship credit and related decisions in regard to publication of the results of this study  
will comply  with the GPP3 guidelines.
The Sponsor retains the right to review all proposed abstracts, manuscripts, or presentations 
regarding this study  45 days prior to submission for publication/presentation. Any 
information identified by  the Sponsor as confidential must be deleted prior to submission; 
this confidentiality  does not include efficacy  and safet y results. Sponsor review can be 
expedited to meet publication timelines.
10 ETHICS AND GOOD CLINICAL PRACTICE
10.1 Good clinical practice
The study  must be conducted in compliance with this protocol, ICH Guideline E6, any 
relevant supplementary  guidance on GCP, and applicable laws and regulations.
10.2 Informed consent
Eligible patients may only be enrolled in the study  after their parent(s) or LAR provide
written IEC/IRB-approved informed consent. Written informed consent must be obtained 
by the Investigator or designee prior to initiation of any study  procedures. In the event of 
an emergency , verbal consent is acceptable , followed b y written informed consent as soon 
as the situation allows.
The procedure for obtaining informed consent for each individual participating in this 
study , must include adequate explanation of the aims, methods, objectives and potential 
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 63of 69
risks of the study . It must also be explained to parents or LARs that they are completel y 
free to refuse to enter the study , orto withdraw from the st udy at an y time for any  reason.
Written consent must be witnessed and countersigned by the Investigator or a qualified 
designee, as appropriate. In obtaining and documenting informed consent, the Investigator 
must comply  with applicable regulatory  requirements and GCP as outlined in ICH 
Guideline E6 and other relevant guidelines, and the ethical principles having their origin 
in the De claration of Helsinki.
Copies of signed I CFs must be given to the parent(s) or LAR , and the or iginals filed at the 
study  site.
In the event that the parent(s) or LAR aretemporaril y unable or unavailable to sign the 
consent document, an impartial witness must be present during the entire informed consent 
discussion. After the parent(s) or LAR have verbally  consented to participation in the study , 
the witness’s signature must be obtained on the form to attest that the information in the 
ICF was accuratel y explained, and was understood by  the parent(s) or LAR.
The eCRFs for this study  contain a sectio n for documenting the parents’ or LAR’s informed 
consent, and this must be completed appropriately . If new safet y information results in 
significant changes in the benefit -risk assessment for ceftobiprole , the ICF must be 
reviewed and updated. All parents or LARs ofpatients currently  enrolled in the study who 
have not yet completed the treatment or post-treatment phases must be given the new 
information and a copy of the revised ICF, and asked to give their consent to the patient 
continuing in the study .
10.3 Patient confidentiality and data protection
The Investigator must ensure that patient anon ymity  is maintained, and that patients’ 
identities are protected from unauthori sed parties. This includes any electronic data 
generated during the study . In the eCRF, or other documents submitted to the Sponsor, 
patients must be identified only by an identification code, and not by name. 
TheInvestigator must keep a confidential patient identification code list, as described in 
Section 8.3.21 of ICH Guideline E6. The Sponsor is responsible for ensuring compliance 
with all applicable data protection laws.
10.4 Independent Ethics Committees / Institutional Review Boards
This protocol and any accompan ying material provided to the patient, including patient 
information sheets or descriptions of the study  used to obtain informed consent, as well as 
any advertising material and information about any compensation provided to the parent(s) 
or LAR , must be submitted to an IEC/IRB operating in compliance with ICH Guideline E6 
and any relevant supplementary  guidance on GCP, and with applicable laws and 
regulations. Approval from the IEC/I RB must be obtained and documented before starting 
the study .
Amendments made to the protocol after receipt of IEC/IRB approval must also be 
submitted tothe IEC/IRB in accordance with local procedures and applicable laws and 
regulations.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 64of 69
11PROTOCOL VERSION HIS TORY
Date Version Summary of changes
16 May 2022 1.0 –
24 May 2022 2.0 •Addition of the definition of the end of the study
• Addition of adverse events of special interest
• Correction of the timeline for preparation of the clinical study report
11 July 2022 3.0 • Deletion of Section 9.2 Biological sample and bacterial isolate 
retention
20July 2022 4.0 • Updated dose rationale in Section 1.4.3.
• Addition of the option in some circumstances that treatment with 
ceftobiprole may be stopped after 5 days at the discretion of the 
Investigator.
• Clarification that in Inclusion criterion 3, clinical criterion (i), 
references to hypotonia are to muscula r or arterial hypotonia.
• Addition to Inclusion criterion 3 laboratory criterion (d), Interleukin -6 
elevated according to local laboratory thresholds .
• Clarification that for the purposes of Exclusion criterion 4, the patient 
must have proven ventilator -associated pneumonia.
• Change of the duration of systemic antibacterial therapy within 7 days 
before start of study medication from 48 to 72 hours for the purposes of 
Exclusion criterion 12.
• Clarification that during the active treatment period, vital s igns must be 
recorded w ithin 30 minutes before the first study drug administration, 
and then three times daily.
• Section 7.2.7 has been amended to ensure that Special Situations are 
applicable to a patient population aged from ≥ 3days to ≤ 3months.
• Addition of tw o categories to the grading of the severity of adverse 
events.
• Section 7.4.2 has been amended to clarify the recording and reporting 
requirements for events occurring after execution of the study ICF but 
prior to dosing.
9July 2024 5.0 • Amendment of the planned study population to require at least eight 
patients, comprising at least two term neonates and six pre -term 
neonates.
• Reduction of the expected minimum treatment duration from 7 days to 
3 days.
• Clarificat ion of inclusion criterion ‘hypotonia ’by removing‘arterial ’
from inclusion criterion 3(i)
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 65of 69
12REFERENCES
(Abitbol 2014) Abitbol CL, Seeherunvong W, Galarza MG, et al. Neonatal kidney  size and 
function in preterm Infants: What is a true estimate of glomerular filtration rate? 
JPediatr 2014; 164:1026 –31.
(Awad 2014) Awad SS, Rodriguez AH, Chuang YC, et al. A P hase 3 randomized double -
blind comparis on of ceftobiprole medocaril versus ceftazidime plus linezolid for the 
treatment of hospital- acquired pneumonia. Clin I nfect Dis 2014; 59:51 –61.
(Bosheva 2021) Bosheva M, Gujabidze R, Károly  É, et al. A Phase 3, randomized, 
investigator -blinded trial compa ring ceftobiprole with a standard -of-care 
cephalosporin, with or without vancomy cin, for the treatment of pneumonia in 
pediatric patients. Pediatr I nfect Dis J 2021; 40:e222 –9.
(CHMP -PDCO 2009) CHMP and PDCO . Guideline on the investigation of medicinal 
products in the term and preterm neonate . 25 June 2009. EMEA/536810/2008.
(Craig 2008 ) Craig WA, Andes DR. In vivo pharmacod ynamics of ceftobiprole against 
multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob 
Agents Chemother 2008; 52:3492–6.
(Dong 2015) Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch 
Dis Child Fetal Neonatal Ed 2015; 100:F257–63.
(Fleischmann 2021) Fleischmann C, Reichert F, Cassini A, et al. Global incidence and 
mortality  of neonatal sepsis: a systematic review and meta -analysis. Arch Dis Child 
2021; 0:1–8.
(Hamed 2020) Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomy cin 
in Staphylococcus aureus bacteremia: a novel protocol for a double -blind, Phase III 
trial. Future Microbiol 2020; 15:35 –48.
(Lodise 2007) Lodise TP, Pypstra R, Kahn JB, et al. Probability  of target attainment for 
ceftobiprole as derived from a population pharmacokinetic anal ysis of 150 subjects. 
Antimicrob Ag ents Chemother 2007; 51:2378–87.
(Nicholson 2012) Nicholson SC, Welte T, FileTM Jr, et al. A randomised, double -blind 
trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for 
the treatment of patients with community -acquired pneumonia requiring 
hospitalisation. I nt J Antimicrob Agents 2012; 39:240–6.
(Overcash 2021) Overcash JS, Kim C, Keech R, et al. Ceftobiprole compared with 
vancom ycin plus aztreonam in the treatment of acute bacterial skin and skin structure 
infections: results of a phase 3, randomized, double -blind trial (TARGET). Clin 
Infect Dis 2021; 73:e1507–17.
(Rhodin 2009) Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function 
maturation: a quantitative description using weight and postmenstrual age. Pediatr 
Nephrol 2009; 24:67 –76.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 66of 69
(Rubino 2021a) Rubino CM, Cammarata AP, Smits A, et al. Model -based approach for 
optimizing ceftobiprole dosage in pediatric patients. Antimicrob Agents Chemother 
2021 Nov; 65(11):e01206 -21.
(Rubino 2021b) Rubino CM, Polak M, Schröpf S, et al. Pharmacokinetics and safety  of 
ceftobiprole in pediatric patients. Pediatr Infect Dis J 2021; 40:997–1003.
(Shane 2017) Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet 2017; 390:
1770–80.
(Schwartz 2009) Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate 
GFR in children with CKD. J Am Soc Nephrol 2009; 20:629–37.
(Troutman 2018) Troutman JA, Sullivan MC, Carr GJ, Fisher J. Development of growth 
equations from longitudinal studies of body weight and height in the full term and 
preterm neonate: from birth to four years postnatal age. Birth Defects Res 2018; 
110:916–32.
(Van den Anker 2006) Van den Anker J (Chair) . Workshop on regulatory  and scientific 
issues related to the investigation of medicinal products intended for neonatal use. 
2006; EMEA/484678/2006.
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 67of 69
13APPENDICES
Appendix 1Renal function
For assessment of renal function, serum creatinine is typically  used after the first week of 
life in term neonates and after 4 weeks in pre -term neonates. Before then, intra -individual 
changes (related to post-menstrual age) in serum creatinine are used as a guide to renal 
function.
In addition, the following references should be considered:
Schwartz and colleagues ( Schwartz 2009) published the following modified formula 
(based on serum creatinine levels determined with the enzy matic method):
Estimated glomerular filtration rate (eGFR ;mL/min/1.73 m2) = 0.413 • length (cm) / 
creatinine (mg/dL) .
Abitbol and colleagues ( Abitbol 2014) reported serum creatinine levels of 
0.68 ± 0.14 mg/dL  during post -natal days 3–7 in 60 pre-term neonates (34 ±3 weeks). 
The same report presented a graph of eGFRs calculated with the modified Schwartz 
formula, in which the values of all age groups were > 20mL/min/1.73 m2. Of note, the 
creatinine -based equation underestimated the GFR compared to the CysC-based 
equations, espec ially in pre -term neonates.
Two graphs presented at an EMA Workshop on regulatory and scientific issues related 
to the investigation of medicinal products intended for neonate use(Van den Anker 
2006) indicated that serum creatinine levels in neonates with a body  weight > 1000 g, 
or a gestational age > 27 weeks, fell from a maximum of about 110 µmol/L  on da y 1 to 
about 50 µmol/L  within 3 to 4 weeks.
Conclusion
Serum creatinine levels are generall y used to monitor renal function (CHMP -PDCO 2009).
Glomerular filtration rate ( GFR )is indirectly  proportional to serum creatinine, i.e., a GFR 
of two-thirds of normal corresponds to a 1.5-fold greater than normal serum creatinine 
level. Since post-menstrual age is the best parameter of kidney  maturation, the following 
creatinine thresholds (determined with the enzy matic method) may  be used to support the 
evaluation of Exclusion criterion 7:
Post-menstrual age
(weeks)Creatinine 
(mg/dL)Rationale
28–34 completed 1.32 150% of the upper limit of the laboratory normal ranges
35–42 completed 1.10 Arithmetic mean of 1.32 and 0.88
> 42 0.88 Upper limit of the laboratory normal ranges of the lower age 
groups and slightly more than 150% of 0.5 mg/d L, the stable 
creatinine level during the first 2 years of life
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 68of 69
Considering these serum creatinine thresholds, a GFR estimated with the modified 
Schwartz formula of less than the values given below might provide evidence of impaired 
renal function or known significant renal disease:
Length (cm ) eGFR threshold (mL/min/1.73 m2)
Post-menstrual age (weeks)
28–34 com pleted 35–42 completed > 42
33 10.3 12.4 15.5
34 10.6 12.8 16.0
35 11.0 13.1 16.4
36 11.3 13.5 16.9
37 11.6 13.9 17.4
38 11.9 14.3 17.8
39 12.2 14.6 18.3
40 12.5 15.0 18.8
41 12.8 15.4 19.2
42 13.1 15.8 19.7
43 13.5 16.1 20.2
44 13.8 16.5 20.7
45 14.1 16.9 21.1
46 14.4 17.3 21.6
47 14.7 17.6 22.1
48 15.0 18.0 22.5
49 15.3 18.4 23.0
50 15.6 18.8 23.5
51 16.0 19.1 23.9
52 16.3 19.5 24.4
53 16.6 19.9 24.9
54 16.9 20.3 25.3
55 17.2 20.7 25.8
56 17.5 21.0 26.3
57 17.8 21.4 26.8
58 18.1 21.8 27.2
59 18.5 22.2 27.7
60 18.8 22.5 28.2
Investigators will exercise their clinical knowledge in conjunction with these thresholds 
when determining the applicability  of Exclusion criterion 7to potential participants in the 
study .
[STUDY_ID_REMOVED]
 Ceftobiprole m edocaril
Clinical Study Protocol
BPR-PIP-003Version 5.0
9July 2024
Confidential –Proprietary  information of Basilea Pharmaceutica International Ltd, Allschwil Page 69of 69
Appendix 2Investigator ’sprotocol signature page
BASILEA
INVESTIGATOR’S PROTOCOL SIGNATURE PAGE
Protocol BPR -PIP-003 Basilea p roduct: Ceftobiprole medocaril
Protocol title:A multicent eropen- label , single -arm, multiple -dose study to evaluate 
the safety, pharmacokinetics ,and efficacy of ceftobiprole medocaril in 
term and pre-term neonates and infants up to 3 months of age with 
late-onset sepsis
Sponsor: Basilea Pharmaceutica International Ltd, Allschwil
Date/ Version : 9 July 2024 / Version 5.0
Name of Principal Investigator: 
Study site: 
I agree to the conditions relating to this study as set out in the above named Protocol and Study  
Procedures. I fully understand that any changes instituted by the Investigator(s) withou t previou s 
discussion with the Sponsor’s Project Clinician, Clinical Pharmacologist and Biostatistician 
(only if required) would constitute a violation of the protocol, including any ancillary studies or 
procedures performed on study patient s (other than those procedures necessary for the wellbeing 
of the patient s).
I agreeto follow International Council for Harmonisation (ICH)guidelines for good clinical 
practice (GCP) , and specifically, to obtain approval from the applicable Independent Ethics 
Committee / Institutional Review Board prior to study start, allow direct access to source 
documents ,and agree to inspection by auditors from the Sponsor and regulatory authorities. I 
will ensure that the investigational product(s) supplied by the Sponsor will be used only as 
described in the protocol for this study , and I ackn owledge that if anyother use is desired, written 
permission must be obtained from the Sponsor .
I acknowledge that I have read the protocol for this study, and I agree to carry out all of 
its terms in accordance with applicable laws and regulations.
Please p rint name and date next to thesignature
Signature Name Date
Principal Investigator
[STUDY_ID_REMOVED]